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COMBINATION OF INVESTIGATIONAL CELL-BASED THERAPY 
AND DEEP BRAIN STIMULATION TO ALTER THE PROGRESSION OF 
PARKINSON’S DISEASE 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
and the motor symptoms are caused by progressive loss of midbrain dopamine neurons. 
There is no current treatment that can slow or reverse PD. Our current “DBS-Plus” clinical 
trial (NCT02369003) features the implantation in vivo of autologous Schwann cells (SCs) 
derived from a patient’s sural nerve into the substantia nigra pars compacta (SNpc) in 
combination with Deep Brain Stimulation (DBS) therapy for treating patients with 
advanced PD. 
The central hypothesis is that transdifferentiated SCs within conditioned nerve tissue 
will deliver pro-regenerative factors to enhance the survival of the degenerating 
dopaminergic cells in the SNpc. The main goal of our studies is to determine if implantation 
of peripheral nerve tissue into SNpc in combination with DBS surgeries is safe, feasible 
and can possibly slow the loss of the midbrain dopamine neurons. First, RNA sequencing 
was used to validate the repair phenotype of human sural nerve tissue two weeks after 
transaction injury. The transcriptomic analysis showed that 3641 genes were differentially 
expressed in conjunction with the upregulation of multiple neurotrophic factors and the 
enhancement of axonogenesis. Secondly, to study the neurobiology of the implant, we 
grafted human nerve implant into the dorsal striatum of athymic nude rats (called Neuro-
Avatars). Immunostaining studies showed a remarkable survival of the implanted human 
SCs up to 6 months post-implantation in Neuro-Avatar animals. In addition, there were 
significant increases in the numbers of surviving human-derived cells in the Neuro-
Avatar's using pre-degenerated human sural nerve tissue as compared to the same sural 
nerve tissue that was harvested in its normal state. 
Finally, we studied data from 27 human subjects with PD that had received DBS 
plus autologous nerve-implants. The safety of the combined intervention and the 
progression of the motor symptoms were evaluated at baseline, 12, and 24 months using 
the Unified Parkinson’s Disease Rating Scale part III (UPDRS). The safety of the studies 
 
 
at 2 years post implantation showed adverse events (AE’s) that were similar to those seen 
with standard DBS therapy. In addition, there was a significant motor improvement on the 
side contralateral to the tissue implantation in comparison to the ipsilateral one. Taken 
together, our data support that combining DBS with in vivo pre-degenerated peripheral 
nerve tissue containing SCs can serve as a safe and promising disease-modifying therapy 
to alter the progression of PD. 
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CHAPTER ONE: INTRODUCTION_UTILIZING PERIPHERAL NERVE 
REGENERATIVE ELEMENTS TO REPAIR DAMAGE IN THE CNS 
 
Abstract 
 An ongoing question in neuroscience is how the peripheral nervous system can 
repair itself following an injury or insult whereas the central nervous system has a 
profoundly limited ability for repair. The recent and rapid advancement of our 
understanding of the gene expression and corresponding biochemical profiles of Schwann 
cells, within the distal segments of injured peripheral nerves, has helped elucidate the 
potential mechanisms underlying the unique ability for these cells to enable regeneration 
of peripheral nerve tissue. Meanwhile, with a new understanding and appreciation for the 
capabilities of the peripheral nervous system, we are beginning to unlock the potential for 
neural regeneration and repair within the central nervous system. The aim of this 
introduction is to briefly outline the historical advancements and the scientific background 
that lead to the concept of utilizing peripheral nerve tissue implants or Schwann cell culture 
implants to serve as repair mechanisms for the central nervous system in the clinical setting 
of spinal cord injury, multiple sclerosis, and neurodegenerative disorders such as 
Parkinson’s disease. 
 
El Seblani, N., Welleford, A., Quintero, J. E., van Horne, C., & Gerhardt, G. A. (2020). 
Invited Review: Utilizing Peripheral Nerve Regenerative Elements to Repair Damage in 
the CNS. Journal of Neuroscience Methods, 108623 (El Seblani, Welleford, Quintero, van 





Historical Perspective of Peripheral Nerves and Their Regenerative Capacity in the 
Central Nervous System 
The interesting and unpredicted finding that peripheral nerves (PN) had the ability 
to regenerate was demonstrated in the 1500’s (1596) when a surgeon, Gabriele Ferrara, 
published his meticulous technique for suturing together the ends of a transected nerve 
following injury (Artico, Cervoni, Nucci, & Giuffre, 1996). Schwann and Schleiden (1847) 
later recognized the complexity and dynamic nature of the PN cells (Schwann & Schleiden, 
1847). Schwann, in his treatise on cell theory, attempted to clarify the origins and 
differences between nerve fibers and their ensheathing components.  Schwann offered 
several possibilities, including that the nerve fibers formed from the membranous 
coalescence of the ensheathing cells. Waller studied and characterized the changes taking 
place in the distal PN segment following disruption or transection, but he did not yet have 
an electron microscope to truly define the reorganization (Waller, 1850). In 1891, Von 
Büngner noted that in the distal segment, Schwann cells (SCs) proliferated and formed 
bands along the remaining collagen components (Koeppen, 2004). These bands are now 
known as “Bands of Büngner”. Büngner noted that this construct was the key component 
allowing the impressive ability of PN to regenerate following injury. It is now understood 
that the Bands of Büngner are formed when transdifferentiated SCs change their profile 
from myelinating into a phagocytic phenotype first and recruit neutrophils and 
macrophages through chemotactic signaling (Lindborg, Mack, & Zigmond, 2017). This 
initiates the Wallerian degeneration, which is important to clear the distal stump of axonal 
and myelin debris. Transdifferentiated SCs disperse along Bands of Büngner to support 





The concept that Wallerian degeneration and Bands of Büngner were important for 
nerve repair was understood by some of the early researchers asking questions regarding 
neuronal plasticity.  One of Cajal’s protégés, Francisco Tello, designed a set of experiments 
in 1911 through which he utilized segments of a sciatic nerve implanted into the cortex of 
rabbits (TELLO, 1913). The nerve was transected 8-14 days before implanting thus 
allowing Wallerian degeneration to occur.  Tello found that predegenerated PN grafts could 
promote CNS regeneration and postulated that the release of neurotrophic substances from 
PN cells played a key role. Cajal later used a microscope and was able to better define not 
only the degenerative changes but also the regenerative potential of PN. While commenting 
on his findings in 1928, Cajal noted that the CNS fibers acted as if “they were attracted by 
an irresistible force” (Cajal, 1928). 
 
Technical signs of progress revitalize the concept of using peripheral nerve implants 
 
 
In the early eighties, Aguayo and his colleagues’ pioneering work with PNS and 
CNS regeneration  has encouraged other investigators to design different grafting 
techniques to test how the PN environment augments the capacity of CNS neurons to 
regenerate and grow new fibers (Aguayo, Björklund, Stenevi, & Carlstedt, 1984; Bray, 
David, Carlstedt, & Aguayo, 1983; Kao, Chang, & Bloodworth Jr, 1977). In addition to 
validating the ability of central axons to regenerate along the PN graft, they observed that 
such regeneration is dependent on the distance between the central neuron cell body and 
the graft location (Richardson & Issa, 1984). 
Axonal regeneration and elongation in response to grafted PN tissue can occur in 





ganglia and the cortex of rats showed that the largest number of neurons grew from the 
striatum (Benfey & Aguayo, 1982). Such an observation indicated that the striatal cells are 
able to regenerate and extend new axons when they are in a close proximity to the PN 
grafts. 
The remarkable collaboration between Aguayo, Björklund, Stenevi, and Carlstedt 
resulted in a finding that highlighted the potential of PN grafts in supporting the viability 
and regeneration of the central neurons in disease states (Aguayo et al., 1984; Gage et al., 
1985). Their animal experiments were undertaken in two stages. In stage I: The 
dopaminergic cells of the striatum were depleted by 6-hydroxydopamine (6-OHDA), a 
state analogous to the striatum pathology in Parkinson’s disease (PD), and grafted with 
mesencephalic rat fetal tissue over the superior colliculus. Then, an approximate 2 cm 
segment of heterologous sciatic nerve was placed in the skull. One end of the nerve was 
connected to the mesencephalic graft, while the other nerve end was left freely hanging 
over the frontal bone. In stage II, two months after stage I, the nerve end over the frontal 
bone was transected and the freshly cut free end was inserted into the already depleted 
dorsal striatum. Five months after implantation, the immunohistochemical staining for 
tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine synthesis, showed that 
the PN grafts were able to support the survival and extension of the axons from the remotely 
implanted fetal mesencephalic neurons into the adult rat striatum. This experiment strongly 
validated that PN grafts have the capacity to promote fetal neuron survival, axonal 
regeneration, and guidance, noted that non-neuronal cells that were known to be supportive 






 The critical role of these non-neuronal cells was highlighted in Anderson’s work 
which demonstrated how nerve axonal growth into freeze-dried PN grafts was suspended 
until SCs invaded the grafts (Anderson et al., 1983). SCs secrete neurotrophic factors in 
the first few days following the nerve injury and have been shown to induce cholinergic 
neuron sprouting in vivo (Carey & Bunge, 1981; Manthorpe et al., 1983). Furthermore, 
examination of the PN grafts at different time intervals up to 12 months post-
transplantation of long nerves into the CNS confirmed that the PN tissue survives and 
myelinates CNS axons (Munz, Rasminsky, Aguayo, Vidal-Sanz, & Devor, 1985). 
Meanwhile, Ebner, Erzurumlu, and Lee recognized the importance of PNS injury 
signals in augmenting the viability and the regenerative capacity of implanted embryonic 
cells within  adult brain environment (Ebner, Erzurumlu, & Lee, 1989). In their 
experiments, they grafted embryonic neocortical cells into the rat cortex of topographically 
injured sensory nerve and measured the extent of the specific thalamic fiber ingrowth and 
activation in the implanted cells. Interestingly, they found that introducing what they called 
a “conditioning lesion” of the PN resulted in an extensive growth and later a functional 
innervation of the implant. Basically, their research raised the question of how damage to 
a PN enhances the regenerative capacity of the central neurons several synapses away. One 
of their main explanations for that observation was that lesioned PN tissue releases growth 
signals and molecules which were transported retrogradely to the distant brain neurons to 
enhance their survival and regeneration. They were able to physiologically record, at 35 
days after grafting, spontaneous and organized discharges of action potentials within the 
implant. Additionally, they demonstrated the growth of thalamic fibers and their terminals 





supported that the CNS has, in fact, a regenerative capacity that could be unleashed in 
response to a specific stimulus and the PNS milieu can be a source for such a stimulus in 
the CNS.  
The regenerative interaction between PN and the CNS was also described in a set 
of elegant experiments by Chi and Dahl who grafted an autologous sciatic nerve into the 
rat CNS (Chi and Dahl, 1983). They performed the transplantation using two techniques. 
The first technique was called the “through-and-through” model during which a segment 
of the sciatic nerve was passed through two craniotomy holes. The second technique was 
a “nerve-within-tube” model during which a small tube of polyethylene containing a nerve 
piece was implanted in the rat CNS. Axonal sprouting from brain tissue to the nerve in the 
“nerve-within-tube” model started as early as 2 weeks post-grafting and was characterized 
by a slow-moving and organized pattern of axonal regeneration. In comparison, the axons 
in the “through-and-through” model followed a disorganized and tortuous type of 
regeneration. That could be a result of different CNS axons exiting the graft and entering 
the brain tissue from the sides. Chi and Dahl also noticed that the axonal fibers in the 
“nerve-within-tube” model were able to grow from the brain into the graft with less damage 
to the brain. Remarkably, they identified “reacting” SCs secreting a unique type of Glial 
Fibrillary Acidic Protein (GFAP) throughout the graft. On average, the nerve grafts 
survived longer with the “through-and-through” model (up to 6 months) in comparison to 
the nerve-within-tube model (2 months). Regeneration of the non-myelinated axons of the 
brain tissue was observed around 1 month while that of the myelinated fibers was not 
observed before 3 months. Central gliosis did not prevent the axonal regeneration but 





tissue were well innervated by new axons, which supported the idea that PN tissue has the 
potential to induce formation and regeneration of axons in the CNS. 
Interestingly, implantation of a PN in rat brain induces the formation of fenestrated 
capillaries within the graft after 5 weeks and myelinated and non-myelinated axons in the 
implant 8 weeks after implantation (Mitchell, Stauber, Anderson, & Mayor, 1985). In their 
attempt to trace the source of the regenerating axons, Mitchell and his colleagues used a 
fluorochrome true blue label, which labeled the cortical areas adjacent to the graft in 
addition to the ipsilateral trigeminal and superior cervical ganglia. The authors could not 
trace the dye to distant CNS areas and concluded that the bulk of the regenerating axons 
originated from pial nerves. Nevertheless, the ability of the central neurons to regenerate 
their axons for a significant distance in an injured CNS environment had been thoroughly 
demonstrated by other research groups (Katzman, Björklund, Owman, Stenevi, & West, 
1971). Björklund and his team, observed that catecholamine fibers were able to sprout after 
iris tissue was grafted into injured rat brain.  
In response to an axonal damage, CNS neuronal cell bodies are at a great risk for 
chromatolysis and retrograde death. Villegas-Perez demonstrated the potential of tibial 
nerve graft to significantly preserve axotomized retinal ganglionic cells (Villegas-Perez, 
Vidal-Sanz, Bray, & Aguayo, 1988) . In addition, they showed that the PN graft guided the 
regenerating axons to synapse with the appropriate CNS targets instead of randomly 
synapsing in the injured CNS. Yet, one of the main limitations of their work was that the 
PN graft had to be anastomosed to the severed optic nerve thus indicating how important 





little axonal growth into the nerve graft when the axons were injured a long distance away 
from the perikarya.  
Later, it was proposed that the gliosis at the interface between the nerve graft and 
the CNS tissue can limit the ability of the CNS originated axons to expand beyond of the 
graft (Bovolenta et al., 1993; Bovolenta and Fernaud-Espinosa, 2000). Yet, recent research 
showed that the axonal regeneration could be further enhanced by modulating the 
extracellular matrix in the CNS.  For instance, applying chondroitinase to CNS lesions 
before/after transplantation of SCs or PN tissue facilitated the regeneration of injured axons 
and restored their functioning (Bradbury et al., 2002; Bradbury and Carter, 2011; Caggiano 
et al., 2005, 2003; DePaul et al., 2015; Fouad et al., 2005; Houle et al., 2006; K R Jessen 
and Mirsky, 2016; Liu et al., 2006). 
Overall, observations from the use of different PN grafting techniques, which were 
mainly pursued in the twentieth century (see Tables 1.1 and 1.2), concluded that: a) certain 
CNS neurons can grow their axons at distances equivalent to the long tracts in rodents that 
join widely separated areas of neuraxis (So and Aguayo, 1985); b) axons of some neurons 
can potentially grow into a longer length after injury  (Bray et al., 1987; Gage et al., 1985; 
Villegas-Perez et al., 1988); c) many of the regenerating axons in the CNS arise from 
injured neurons rather than sprouting from dormant ones (Friedman and Aguayo, 1985); 
d) PN grafts stimulate central axons’ regeneration and significantly enhance the functional 
recovery and early survival of axotomized ganglion cells such as retinal ganglion cells 
(Aguayo et al., 1984; van Horne et al., 1991; Villegas-Perez et al., 1988) and e) grafting 
PN tissue near neuronal cell bodies upregulates the expression of regeneration-associated 





and Jenkins, 1993; Schaden et al., 1994; Tetzlaff et al., 1991), which support the extension 
of regenerating axons into the CNS. The question then becomes, where does the capacity 
of the PN to regenerate come from? Findings from a wide variety of studies support that 
the unique repair cell properties of SCs are the key. 
 
The Role of Schwann Cells in Neuronal Survival and Axonal Regeneration  
SCs derive from the neural crest cells which initially differentiate into Schwann 
cell precursor. Eventually, immature SCs mature into myelin-forming and non-myelin 
(Remak) SCs (Frostick et al., 1998; Jessen et al., 2015; Jessen and Mirsky, 2005). In 
addition to maintenance of the axonal sheath and myelin production, the myelin-forming 
and Remak SCs play a crucial role in the Wallerian degeneration of PN (Figure 1.1). About 
a week after an axonal injury, those SCs start to divide and form Bungner’s bands, which 
accept newly regenerating sprouts from the proximal axonal stumps (Gomez-Sanchez et 
al., 2017). In fact, these dividing SCs acquire a novel phenotype with new characteristics 
in addition to regaining some traits from their undifferentiated precursor state (Figure 1.1). 
  
i. SCs re-express the molecules that characterize immature SCs in developing nerves, 
including L1 adhesion molecule, p75 neurotrophin receptor (p75NTR), and glial 
fibrillary acidic protein (GFAP) their precursors before being turned into myelinating 





ii. Acutely after a nerve injury, reprogrammed SCs downregulate myelinating genes and 
their related-transcription factors like Egr2 (Krox20), myelin-associated glycoprotein 
(MAG), and periaxin (Arthur-Farraj et al., 2012; Fazal et al., 2015). 
iii. SCs secrete neurotrophic factors like nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5, ciliary neurotrophic 
factors (CNTF), and glial-cell line derived neurotrophic factor (GDNF) (Chan et al., 
2004; Höke et al., 2003; Ma et al., 2011; Michailov et al., 2004; Taveggia et al., 2005). 
However, it is worth noting that changes in these factors differ in timing and site of 
nerve injury. The upregulation of the neurotrophic factors tends to be higher in the distal 
portion of an injured nerve during the acute phase of the injury (Boyd and Gordon, 2003; 
Chen et al., 2007). SCs also secrete cytokines to recruit macrophages and neutrophils 
(Lindborg et al., 2017). Some of these cytokines, like LIF and IL-6, act directly on 
neurons to promote survival.  Later, the recruited macrophages act as a maintaining 
source of vital cytokines as the macrophages are polarized by the SCs toward an 
alternative, the M2 phenotype. This phenotype promotes axonal outgrowth by releasing 
essential anti-inflammatory mediators like IL10, arginase-1, chitinase-like 3/YM1, and 
mannose receptor C type 1/CD206 (Al-Darraji et al., 2018; Haydar et al., 2019; Kroner 
et al., 2014). 
iv. SCs release VEGF and other factors to promote vascularization (Barrette et al., 2008). 
v. Together with macrophages, SCs clear the myelin that inhibits new axon regeneration 





vi. SCs form regeneration columns which are known as bands of Büngner. These bands are 
important in guiding the newly regenerating axons to their correct targets (Jessen et al., 
2015). 
 
Signaling pathways and mechanisms involved in reprogramming SCs 
 
The emergence of the SCs’ repair phenotype is controlled mainly by the 
transcriptional factor c-Jun (K R Jessen and Mirsky, 2016). Activation of other 
transcription factors like Sox2, Id4 and Pax3 is also essential in initiating the 
reprogramming  process, but what differentiates c-Jun from other transcriptional factors is 
that it  simultaneously downregulates  myelinating genes and upregulates regeneration-
associated genes (Parkinson et al., 2008).  
How c-Jun is activated remains unclear but inhibiting the activity of SCs’ c-Jun 
greatly reduces the regenerative capacity of injured PN. Normally, c-Jun is suppressed by 
Krox-20 in myelinating SCs. However, upon nerve injury, c-Jun becomes activated in the 
distal stump (Arthur-Farraj et al., 2012; Chen et al., 2002; Parkinson et al., 2008). Jessen 
and Mirsky’s group in 2012 used a c-Jun knock out mouse model to study the role of c-Jun 
in the trans-differentiation of SCs after PN injury. The nerves of c-Jun mutant mice 
appeared like those of wild type mice before injury. However, after an injury, a comparison 
of the distal nerve stumps of wild type and c-Jun knock out mice showed that a remarkable 
number of genes involved in regeneration and trophic support, like BDNF, GDNF, Artn, 
Shh, and GAP-43, failed to upregulate. On the other hand, myelin-related genes such as 





Importantly, reactivation of c-Jun by adenovirus transfer upregulated BDNF and GDNF 
expression and fully restored the number of axons after injury(Arthur-Farraj et al., 2012). 
The c-Jun signaling pathway also affects neuronal cell adhesion processes. Injured 
nerves, from c-Jun knockout mice, expressed reduced N-cadherin and p75NTR but 
elevated levels of NCAM (Arthur-Farraj et al., 2012). In addition to N-cadherin and 
NCAM, Neurofascin-155, TAG-1, and Gliomedin are other major cell adhesion 
proteins that are expressed during the regeneration process. Additionally, other studies 
reported that SCs produce extracellular matrix molecules (like Fibronectin, Collagen I and 
IV, and Laminin) that facilitate and guide axonal growth in PN environment (Eshed et al., 
2005; Spiegel and Peles, 2006; Tait et al., 2000; Traka et al., 2002).  
Despite the major role of c-Jun in inducing the repair cell phenotype of SCs, other 
transcriptional factors can act independently of c-Jun. For instance, the function of Sox-2, 
a regeneration associated protein, is not affected by knocking down c-Jun after a nerve 
injury (Arthur-Farraj et al., 2017, 2012). Nevertheless, the key function of the repair SCs 
phenotype in preventing the neuronal death relies heavily on the activation of c-
Jun. Selectively mutating c-Jun in SCs reduces the number of DRG neurons by about 50 
% after an injury to PN. Interestingly, the number of proliferating SCs in the c-Jun 
knockout mice was comparable to that of the wild type animals thus demonstrating that the 
lack of axon regeneration and the increased neuronal death in c-Jun knock outs was 
dependent on the new SCs’ phenotype rather than simply their proliferation.  
The complete chain of events leading to c-Jun activation after PN injury has yet to 
be fully elucidated. The events below describe the set of signaling pathways that are 





activated intracellularly in response to an injury including Erk1/2, JNK, and p38. These are 
important regulators of the AP-1 transcriptional complex of which c-Jun is a key 
component  (Harrisingh et al., 2004; Napoli et al., 2012, 2009; Yang et al., 2012). 
Activation of the Raf / ERK pathway with and without a nerve injury initiates the repair 
phenotype of the SCs and induces a robust inflammatory response. This response is 
reversible when the Raf/ERK pathway is switched-off (K. R. Jessen and Mirsky, 2016). 
Furthermore, switching into the migratory repair phenotype is crucial for SCs to 
form the regenerative tracks that cross-bridge the wound site. Formation of a new 
extracellular matrix is crucial for SCs to travel along the regenerative tracks. Ephrin B 
expressed by the fibroblasts activates EphB2 receptor on SCs which then induces the 
relocalization of N-cadherin to the SC surface through the Sox2 transcription factor (Jessen 
et al., 2015; Parrinello et al., 2010). While the extracellular tissue that is bridging the wound 
sites is initially not vascularized, it becomes hypoxic. The macrophages sense the ongoing 
hypoxia and secrete VEGFA, that is vital to induce the vascularization of the bridge and 
subsequent SC migration (for review see Cattin et al, 2016, Stierli S, Glia 2019). Formation 
and maintenance of the regeneration tracks by repair SCs, bands of Büngner, is decisive 
for guiding the regenerating axons back to the terminal SCs at the original targets while 
providing the essential trophic factors to support the survival of the proximally injured 
neurons. 
The repair capacity of SCs is increasingly motivating the curiosity of researchers. 
A better understanding of this repair phenotype and how it is activated may, in the future, 
change our ability to treat injury or damage in the CNS for conditions such as 





investigated the role of the Hippo/YAP (Yes-associated protein) pathway in controlling the 
repair capacity of SCs (Mindos et al., 2017). Using a sciatic nerve crush injury model in 
mice, Merlin-null nerves had a severely impaired axonal regeneration and remyelinating 
capacity. The failure of Merlin-null nerves to repair was mediated by activating YAP, 
which is a major Hippo pathway effector. To better test the relationship between YAP and 
c-Jun expression, rat SCs were infected with adenovirus expressing the YAP protein. YAP 
was localized to the nucleus and was associated with a significant downregulation of c-Jun 
(Mindos et al., 2017). On the other hand, removing YAP restores c-Jun levels, neurotrophin 
expression, and the functional recovery of the nerve after an injury. Taken together, these 
findings indicate that Merlin expression and YAP inhibition help in switching SCs into 
their repair phenotype. 
Finally, the complexity of the different layers involved in driving the repair 
phenotype of SCs has yet to be fully investigated. The recent work published by Arthur-
Faraj et al. raised several questions regarding the role of the appropriate regulation of 
epigenetics for a proper repair of injured nerves. For instance, c-Jun-null nerves expressed 
significantly lower levels of miR-21a-5p and miR-34b than controls. In contrast, other 
miRNAs (miR96-5p, miR-124-3p, miR-183-5p, and miR-204-5p) were significantly 
overexpressed (Arthur-Farraj et al., 2017). What is the physiological importance of such 
micro RNAs and others in the repair process? Only the recent advances in the epigentic 






Pre-clinical and clinical studies 
Next, we review the preclinical and clinical literature exploring the hypothesis that 
grafting PN tissue into the CNS might be utilized as a therapeutic approach to helping 
repair the CNS and, in part, slow down, halt, or reverse the progression of PD and other 
neurodegenerative diseases by employing the “repair cell’ properties of SCs. Ultimately, 
we ask: can we use the signaling properties of the SC to explore how to repair the CNS? 
Use of SC implants in spinal cord repair research 
Several groups have tried to implement the regenerative properties of SCs to repair 
the spinal cord after an injury. In different animal models of spinal cord injury, 
transplantation of SCs has demonstrated tissue preservation, axonal regeneration and 
myelination in addition to functional recovery (Kanno et al., 2014; Pearse et al., 2004; 
Takami et al., 2002). To enhance the viability of transplanted SCs and reduce the 
astrogliosis in an injured spinal cord, different matrices have been used to suspend SCs 
pre-transplantation like Matrigel, Puramatrix, and Alginic acid sodium hydrogel (Kanno et 
al., 2015; Moradi et al., 2012). These matrices were composed of a variety of extracellular 
matrix components including collagen type IV, heparin sulfate proteoglycans, and 
entactins (Kanno et al., 2014; Pearse et al., 2007). Additionally, several transplantation 
methods were investigated to augment SCs survival and axonal regeneration including co-
transplanting bone marrow stem cells (BMSCs) with genetically engineering SCs that 
produce different neurotrophic factors (Table 1.1). The migration of SCs within the host 





by adding chondroitinase ABC to SCs or PN grafts with or without acidic fibroblast growth 
factors (Bradbury and Carter, 2011; DePaul et al., 2015; Kanno et al., 2014; Zhao and 
Fawcett, 2013). Chondroitinase degrades the chondroitin sulfate proteoglycans, which is 
secreted by the astrocytes and leads to the formation of the glial scar. Also, grafting SCs 
with olfactory ensheathing cells after spinal cord contusion unduces axonal growth and the 
functional outcome (Fouad et al., 2005; Pearse et al., 2007; Ramón-Cueto and Avila, 1998). 
Furthermore, co-transplantation of SCs with neural stem cells and bone marrow 
mesenchymal stem cells overexpressing trophic factors promotes neuronal differentiation, 
neuroprotection and outgrowth of serotonergic fibers, and enhances locomotor recovery 
(Oraee-Yazdani et al., 2016; Pourheydar et al., 2012; Yazdani et al., 2013). 
The preclinical work by Bastidas et al. (2017) investigated the use of cultured 
human SCs to repair an injured spinal cord. Xenografts of human SCs were transplanted 
into the spinal cord of nude rats and demonstrated both safety and ability of the cells to 
survive and support histological regeneration and functional recovery of the CNS (Bastidas 
et al., 2017). To study the role of human SCs in treating demyelinating diseases like 
multiple sclerosis, Kohama and colleagues implanted human SCs in a demyelinating rat 
spinal cord. Five weeks after transplantation, the electrophysiological recordings and 
immunohistochemistry analysis showed a prominent survival of the transplanted human 
SCs and extensive myelination with an increase in average conduction velocity (Kohama 
et al., 2001). Thus, SCs which are normally contained in PN, can survive transplantation 
and promote neural repair in a model of demyelinating diseases.  
Meanwhile, Saberi group has tested autologous SCs transplantation on 33 human 





transplantation, study participants did not show any clinical improvement. Three to four 
million cultured SC’s were injected into the injury site of the spinal cord (Saberi et al., 
2008). After two years, MRI results showed no evidence of abnormal tissue or tumor 
growth at the injection sites. Clinical assessments showed significant improvement in the 
sensory light touch test but no improvement in the pinprick sensation test. Only subtle 
motor improvements were reported in the cases where the spinal cord injury had occurred 
within three years; however, there were no significant improvements in sexual, sphincteric, 
or functional assessments (Saberi et al., 2011). The lack of a significant improvement after 
the transplantation could be due to many reasons including the chronic changes that might 
have occurred between the injury onset and the transplantation timing. A larger enrollment 
of participants along with a longer follow-up period could help clarify the potential clinical 
significance of the effects this cell-based intervention. On the other hand, additional 
elements of PN tissue, namely the macrophages, neutrophils, fibroblasts and disintegrated 
axonal cytoskeleton, are needed to support the function of SCs and allow appropriate repair 
of injured or degenerating CNS cells. 
The first clinical trial under FDA approval was an open-label, unblinded, 
nonrandomized and non-placebo-controlled Phase I study that involved six subjects with 
subacute spinal cord injury. The primary endpoints of the trial were to evaluate the safety 
and feasibility of implanting cultured SCs intro an injured spinal cord. Autologous SCs 
were cultured in vitro from sural nerve and injected into the lesioned spinal cord. One year 
after grafting, there were no major surgical, medical, or neurological adverse events related 






Human experience with implantation of SCs in neurodegenerative diseases 
Neurodegenerative diseases, such as Alzheimer’s and PD are complex, chronic 
disorders with cognitive and motor symptoms that result from the progressive neuronal 
loss within cortical and subcortical areas of the human brain. The current pharmacological 
treatments act on symptoms without slowing or reversing the ongoing deterioration in 
neurons and their function. Nevertheless, preclinical research shows that at earlier 
pathological stages, the neurons retain some characteristics to recover if they get enriched 
with optimal neurotrophic media, such as NGF, BDNF or GDNF (Quintino et al., 2019). 
Different “repair” strategies have been proposed to treat or replace degenerating neurons 
in the CNS, especially in PD. These therapeutic strategies include transplantation of fetal 
ventral mesencephalic tissue (Bakay, 1993; Freed et al., 2011, 2001; Hallett et al., 2014; 
J.H. et al., 2017; Kordower et al., 2000; Li et al., 2008; Olanow and Fahn, 2006), delivering 
neurotrophic factors to degenerating areas of the CNS (Kordower et al., 2000; Lindahl et 
al., 2017; Slevin et al., 2007; Sullivan and O’Keeffe, 2016; Whone et al., 2019), and 
autologous PN grafting (van Horne et al., 2018, 2016). Previous and current clinical 
attempts to restore neuronal loss by transplanting fetal ventral mesencephalic tissue have 
faced serious ethical and technical challenges although a few subjects did show some 
improvement. We would argue that because of the ability of SCs to support neuronal 
recovery in PNS, we may gain further insight into neuroregeneration through examining 
these experimental models of grafting SCs in the CNS. Unfortunately, great difficulties 





Neurotrophic Factors as Putative Therapies 
Pilot studies that have investigated the delivery of neurotrophic factors like GDNF 
(Hoffer et al. 1994, Gash et al. 1996, Gash et al. 2005, Grondin et al. 2002, Grondin et al. 
2019),  Neurturin (Reosenblad et al. 1999; Oiwa et al. 2002, Gasmi et al., 2007, Grondin 
et al. 2008),  cerebral dopaminergic neurotrophic factor (CDNF; Voutilainen et al. 2011, 
Airavaara et al. 2012), or BDNF (Tsukahara et al. 1995, Yurek et al. 1996),  have shown 
considerable promise in promoting, restoring or protecting dopamine containing fibers and 
neurons. These are the primary type of neuronal cells affected in PD and are affected in 
rodent and nonhuman primate models of dopamine depletion. Furthermore, co-
administration of  GDNF with NT-4/5,  has a synergistic effect on increasing dopaminergic 
neuron survival and stimulating dopamine release in rat organotypic explants (Di Santo 
and Widmer, 2018). Nevertheless, the use of neurotrophic factors in humans, either by 
direct delivery of GDNF (Nutt et al. 2003, Gill et al. 2003, Patel et al. 2013, Slevin et al. 
2005, Lang et al. 2006), platelet-derived growth factor (PDGF-BB, Paul et al. 2015) or 
AAV delivery of Neurturin (Marks et al. 2008, Marks et al. 2010, Bartus et al. 2013, 
Olanow et al. 2015), have shown limited clinical benefits while identifying practical 
dilemmas concerning the specificity of the therapeutic target. In addition, manufacturing 
and purification of biologics, such as growth factors, is expensive, complicated, and can 
complicate their use. Penetration of the neurotrophic proteins into brain parenchyma was 
so problematic that a need evolved for direct versus gene therapy-based approaches to CNS 
delivery (Marks et al., 2015, 2010; Salvatore et al., 2006). Recently, to improve striatal 
GDNF exposure and optimize the pharmacodynamics and pharmacokinetics of GDNF, a 





delivery of GDNF (Whone et al. 2019). The drug was administered intermittently every 4 
weeks for 40 weeks using an intra-putamenal and bilateral skull-mounted, multi-cannula 
transcutaneous port device (Whone et al., 2019). The study failed to meet its primary 
endpoints, but a subsequent analysis of the extended treatment (80 weeks) showed 
significant differences in motor activity and quality of daily living. But if the trophic factor 
hypothesis remains valid, one question becomes: is one growth factor enough to slow or 
stop the degeneration and/or restore injured neurons in the nigrostriatal system?  
SCs within the autologous nerve grafts may serve as an alternative and natural 
delivery source of many “repair molecules” including neurotrophic factors After 
experimental results (Watts et al., 1997) demonstrated no major functional improvement, 
possibly in part because of sample size limitations (only 5 participants), this area of 
research had been suspended for more than two decades. Nevertheless, that trial and a 
recent, single-case transplantation (Tabakow et al., 2014) of repair SCs, in the form of PN 
grafts in combination with olfactory ensheathing cells, were able to show safety of the 
procedure and some indications of possible efficacy. This work has helped revitalize the 
concept of potentially using PN grafts in repairing the CNS.  
PN grafting in nonhuman primate models of neurodegenerative diseases 
Preclinical and clinical attempts to restore the nigrostriatal dopaminergic pathway 
using dopamine secreting cells located within adrenal medulla grafts and human fetal 
mesencephalic tissue were carried out in the 1980’s to possibly treat PD. Autologous 
adrenal medullary transplantation alone resulted in poor graft survival while the human 





and Björklund, 1987). However, co-grafting adrenal medullary tissue with an autologous 
PN tissue was tested by Watts and his team in n-methyl-4-phenyl-1,2,3,6 
tetrahydropyridine (MPTP)-treated parkinsonian monkeys (Date et al., 1990; Watts et al., 
1997, 1995). Two small cavities were created in the caudate nucleus of two monkeys. Each 
cavity was implanted with an adrenal medulla-sural nerve co-graft. Dexamethasone and 
nonsteroidal anti-inflammatory drugs were administered postoperatively. The grafted 
monkeys demonstrated significant improvements in their parkinsonian motor scores 6 
months after the surgery. These results were also supported by EMG traces with increased 
peak velocity of movements after grafting. Their study was unblinded and lacked surgical 
sham controls thereby limiting the scientific judgment of the effect of the graft versus the 
surgery itself on the study outcomes. However, this research group was able to 
histologically demonstrate prolonged survival of the adrenal medulla cells along with the 
peripheral SCs for months after the grafting procedure. These results may reflect the 
potential of the PN grafts in biodelivering adequate trophic support to enhance the survival 
of adrenal medullary cells and possibly repair the damaged host neurons at earlier stages 
of a neurodegenerative disease. 
Clinical trials investigating the potential of PN cell / tissue-based grafts to repair the 
CNS 
The concept of tissue transplantation into the CNS has been explored as a therapy 
for the treatment of multiple conditions, including PD (Freed et al., 2011), multiple 
sclerosis (Stangel, 2004), Huntington’s disease (Bachoud-Lévi et al., 2006; Gaura et al., 





implanting autologous PN grafts in combination with other tissues into the CNS is 
supported by the results of investigations in both non-human primate models (Levi et al., 
2002) and in patients with PD (Watts et al., 1997). Following positive results in a study 
examining the efficacy of intrastriatal co-grafts of autologous adrenal medulla and sural 
nerve in a macaque model of PD (Watts et al., 1995), the research team placed similar co-
grafts in the basal ganglia of five human subjects with advanced PD (Watts et al., 1997). 
Segments of the 11th intercostal nerve were harvested and stereotactically placed, together 
with autologous adrenal medullary tissue, into the caudate nucleus and, putamen. The 
concept was that SCs from transected PN segments could produce NGF to enhance the 
survivability of transplanted adrenal chromaffin cells and the recovery of the host 
nigrostriatal system (Date et al., 1990). Overall, the human surgery was reported to result 
in no major complications and was ultimately deemed both safe and successful. The two-
year follow-up showed a mild to moderate improvement in Unified Parkinson’s Disease 
Rating Scale (UPDRS) motor scores; yet, the improvement was not statistically significant. 
This could be explained by the small sample size and the chosen locations of the grafts. 
The safety of transplantation into the basal ganglia has been demonstrated by 
Mendez et al. by placing fetal cell suspensions bilaterally into the substantia nigra, as well 
as the putamen, without any perioperative or long-term complications (Mendez et al., 
2002). Meanwhile in 2001, Timothy Vollmer and his team at Yale implanted autologous 
SCs into lesions in the frontal lobe of the brains of patients with multiple sclerosis. While, 
to our knowledge, the results were never published, reports from the funding agency state 
the surgical procedure was safe, with no adverse effects from the transplantation (The 





transplanting purified SCs into the brain or spinal cord (Anderson et al., 2017; Kohama et 
al., 2001; Pizzorusso et al., 1994; Saberi et al., 2011, 2008).  One of the key benefits of 
implanting autologous SCs is that each patient could serve as his/her own donor, thus 
minimizing the need for immunosuppression (Stangel, 2004). 
 Could it be that perhaps because of these unpromising clinical results, and the rising 
trend in the use of single growth factors such as GDNF or Neurturin to restore 
dopaminergic function in PD (Funakoshi et al., 1993; Gash et al., 1996; Kordower et al., 
2000; Slevin et al., 2007) the therapeutic benefits of PN grafts for treating CNS disorders 
have been undervalued over the past two decades? In addition, an emerging understanding 
of the PN repair process helped further incorporate this cell-based therapeutic into clinical 
trials (see Tables 1.1 and 1.2). 
Using regenerative PN implants in PD to alter disease progression 
In 2013 our research group initiated the first clinical trial to investigate the 
hypothesis of using autologous PN grafts as a source of SCs to deliver crucial repair 
molecules to the degenerating dopaminergic neurons in the SN of patients with PD 
undergoing deep brain stimulation (DBS) surgery (Figure 1.2) (van Horne et al., 2018, 
2016). The goal of the trial was to determine the safety and feasibility of implanting PN 
grafts at the time of DBS surgery. This was the first clinical study that investigated the use 
of autologous PN grafting in conjunction with DBS, an FDA-approved adjunctive therapy 
to treat the symptoms of PD. The participants were tested with the DBS system turned off 
and medications removed to washout their effects. Eight participants (6 males and 2 





years, and mean disease-duration of 10 ± 4 years. All the participants consented for DBS 
surgery targeting the subthalamic nucleus (STN) and for sural nerve grafting to the 
substantia nigra (a procedure we have termed DBS Plus). The surgeries were done in two 
stages on two different days (van Horne et al., 2015) (Figure 1.2).  
During the first stage, the sural nerve was exposed and transected. The initial injury 
to the nerve was expected to stimulate the SCs to reprogram themselves into the “repair 
cell” phenotype as described previously in this review. The second stage was done 3-5 days 
later, during which DBS electrodes were inserted bilaterally followed by unilateral grafting 
of distal sural nerve fascicles, approximately 5 segments each about 1 mm in length into 
the SN, contralateral to the most affected side. The targeting of the DBS electrodes and the 
graft target location were confirmed to be accurate by postoperative 1.5 T MRI.  
Adverse events of the grafting were comparable to that of DBS surgery alone. The 
postoperative follow-up at 12 months reflected safety and tolerability of the grafting 
procedure (van Horne et al., 2018). Only one participant suffered from superficial cellulitis 
at the sural nerve incision site and 3 participants reported numbness along the sural nerve 
dermatome. MRI of the midbrain showed no abnormalities acutely or at 12 months after 
the surgery. Motoric impairment was measured using the UPDRS Part III while 
participants were off therapy at 12 months. The mean scores were, 25 ± 16 points at 12 
months vs 33 ± 10 points at baseline. The UPDRS test is scaled from 0-108 points, 0 is not 
affected and 108 being most affected). This pilot study was able to reflect the safety and 
feasibility of transplanting autologous SCs within conditioned PN tissue into the human 





we have optimized the sample size in our ongoing studies (clinicaltrials.gov, registration 
no. NCT02369003).  
Our current ongoing studies (NCT02369003) have included patients who receive 
DBS electrodes to the internal segment of the Globus Pallidus (GPi), another target for 
DBS. One benefit of this approach is that the location is remote enough from the SN that 
the grafts can be readily visualized with MR imaging. In addition to MRIs, SPECT imaging 
using the radioligand, Iofluopane I123 injection (DaTscan™) has been implemented to 
evaluate dopamine neuronal function in participants pre- and post-implantation of the sural 
nerve grafts 
In our studies, transplanting repair SCs within PN autografts is being investigated 
as a conceivable disease-modifying therapy in PD. With no known cures, disease 
modification remains one of the greatest unmet medical needs in the treatment of 
neurodegenerative diseases like PD (Kalia et al., 2015). We continue to investigate 
questions regarding dosing and optimization of bilateral placements of the PN grafts to 
help lay the foundation for a blinded Phase II trial to better determine the efficacy of the 




Table 1. 1 Critical studies that investigated the use of peripheral nerve tissue components in treating trauma and spinal cord 
injury. 
 




Experimental Design Model Results 
(David & 
Aguayo, 1981) 
PN graft alone Bridging model in 
transected model of 
SCI in rats 
Regenerating axons were guided by the PN 
graft from the medulla oblongata to the lower 





Graft of SCs + BDNF + NT-3 Transection model 
of SCI in rats 
Neurotrophins infused with the graft enhanced 
propriospinal axonal regeneration and 
promoted axonal regeneration of specific 
distant populations of brain stem neurons into 
the grafts 
(Ramón-Cueto 
& Avila, 1998) 
Combined SC-filled guidance 
channels + OECs transplants 
Transection model 
of SCI in rats 
Robust ingrowth of 5HT-positive axons across 
SC graft–cord interfaces and promotion of 
long-distance regeneration of descending 
supraspinal and ascending propriospinal axons 
(Levi et al., 
2002) 
Intercostal nerve autografts + 
fibrin glue containing aFGF 
Transection model 
of SCI in 
Cynomolgus 
monkeys  
Regeneration of theproximal spinal axons into 
the PN grafts; the grafts significantly enhanced 
the regeneration of myelinated axons into the 








Table 1.1(Continued)  
(Takami et al., 
2002) 
Co-graft of OE glia and cultured 
SCs  
Contusion model of 
SCI in rats 
At 12 weeks after injury, SC-containing grafts 
expressed more intense staining for glial 
fibrillary acidic protein and chondroitin sulfate 
proteoglycan compared with OEC-only grafts. 
Propriospinal and brainstem axons reaching 5–
6 mm beyond the grafted area.  SC graft is more 
effective in promoting axonal 
sparing/regeneration than an SC/OEC or OEC 
graft in the moderately contused adult rat 
thoracic spinal cord 
(Pearse et al., 
2004) 
Schwann cell grafts with 
phosphodiesterase IV inhibitor 
(Rolipram) 
Contusion model of 
SCI in rats 
Inhibition of cAMP hydrolysis by the 
phosphodiesterase IV inhibitor rolipram 
promoted significant supraspinal and 
proprioceptive axon sparing and myelination 
(Fouad et al., 
2005) 
Graft of SCs/OECs + 
Chondroitinase ABC 
Transection model 
of SCI in rats 
Increased numbers of both myelinated axons in 
the SC bridge and serotonergic fibers that grew 
through the bridge and into the caudal spinal 
cord 
 (Pearse et al., 
2007) 
Co-grafts of SCs cultured from 
sciatic nerves + OEC  
Contusion model of 
SCI in rats 
At 9 weeks post-implantation, OEC grafts 
showed improved survival when transplanted 
with SCs; modest improvements in open-field 








Table 1.1(Continued)  
(Golden et al., 
2007) 
Grafts of SCs transduced with 
D15A neurotrophic factor 
Contusion model of 
SCI in rats 
At 6 weeks post-transplantation, SCs survived, 
myelinated 5-HT, DβH, and CGRP axons and 
their lengths were up to 5-times longer within 




Grafting of SCs with prolonged 
ChABC infusion 
Contusion model of 
SCI in rats 
Regrowth of raphe-spinal fibers from the brain 
stem areas (vestibular nuclei and reticular 
formation) into the SC bridge 
(Ma et al., 
2010)  
Sural nerve transplants + aFGF Transection model 
of SCI in monkeys 
Improvement in walking performance at 16 
weeks after surgery   
(Moradi et al., 
2012)  
Xenografts of human fetal SCs 
encapsulated in PuraMatrix 
scaffold 
Contusion model of 
SCI in rats 
At 8 weeks post-transplantation, grafted SCs 
infiltrated the injury site, suggesting that 
PuraMatrix may play an important role in the 




BMSCs + SCs Contusion model of 
SCI in rats 
At 8 weeks post-transplantation, SCs survived 
around the injury site, co-transplanted animals 













Ozawa, Itoi, & 
Bunge, 2015; 
Kanno et al., 
2014) 
Graft of SCs transduced with 
D15A neurotrophic factor + 
ChABC 
Contusion model of 
SCI in rats 
Increase of axonal regeneration caudal to the 
graft; increase of locomotor and sensory 
function 
(DePaul et al., 
2015) 
Graft of PN + aFGF + ChABC Transection model 
of SCI in mice 
Regeneration of serotonergic and tyrosine 
hydroxylase-positive axons across the lesion; 
cytometry analysis and external urethral 
sphincter electromyograms showed improved 




Xenografts of human SCs Contusion model of 
SCI in rats 
At 6 months post-transplantation, there was no 
evidence of tumorigenicity with preservation of 
the white matter as well as axon growth and 
myelination 
 
Clinical Trials    
(Tadie et al., 
2002) 
Surgical bypass using segments 
of autologous sural nerve from 
thoracic cord levels into the 
lumbar ventral roots 
Humans with chronic 
SCI (N=1) 
At 8 months after transplantation, partial return 
of motor function in the paralyzed legs after 
nerve autografts 
(Saberi et al., 
2011; Saberi et 
al., 2008) 
Intramedullary graft of 
autologous SCs cultured from 
sural nerve 
Humans with SCI for 
≥6 months (N=33) 
At two years follow up, no major adverse 
events were reported, but statistical 
improvement in sensory scores. The duration 
of SCI had no significant influence on sensory 
results. Significant motor changes were 








Table 1.1(Continued)  
(Zhou et al., 
2012)  
Autologous SCs cultured from 
sural nerve + 
Neurorehabilitation  
Humans with SCI 
1wk-20 months after 
injury (N=6) 
At 5 years of follow-up, grafting procedure was 
feasible, safe, with mild to moderate clinical 
improvement on ASIA motor and sensory 
index; Smaller volume of myelomalacia and 
cystic degeneration after SCs transplantation. 
(Amr et al., 
2014) 
Combined sural nerve grafts + 
chitosan-laminin scaffold + 
BMSCs 
Humans with chronic 
SCI (N=14) 
Mild to moderate motor and sensory 
improvements in the lower limbs; regaining 




Co-grafts of autologous sural 
nerve + OEC 
Humans with SCI 
(N=1) 
At 19 months post-transplantation, no adverse 
effects observed; Functional regeneration of 
both efferent and afferent long-distance fibers; 
partial bridging of the spinal cord at the nerve 
grafts; Neurophysiological restitution of the 
integrity of the corticospinal tracts 
(Yazdani et al., 
2013) 
Combined intrathecal injection 
of autologous SCs + MSCs 
Humans with chronic 
SCI (N=6) 
No evidence of tumor overgrowth observed in 
MR imaging for a mean of three years after cell 









Table 1.1(Continued)    





subacute SCI (N=6) 
At 1-year post-transplantation, no serious 
adverse events related to the cell therapy were 
reported. There was no evidence of additional 
spinal cord damage, mass lesion, or syrinx 
formation. In one patient, there was an 
atrophy and focal tethering of the spinal cord 
    
 
PN: Peripheral nerve, SCI: Spinal cord injury; BDNF: Brain derived neurotrophic factor; NT-3: Neurotrophin-3; 5-HT: 5-
hydroxytryptamine, aFGF: acidic fibroblasts growth factor; OEC: Olfactory ensheathing cells; DβH: dopamine-β-hydroxylase; 
CGRP: Calcitonin gene-related peptide; BMSCs; Bone marrow stromal cells; MSCs: Mesenchymal stem cells; SAPNS: self‐












Table 1. 2 Critical studies that investigated the use of peripheral nerve tissue components in treating demyelinating and 
neurodegenerative diseases. 
Demyelinating and Neurodegenerative Pathologies 
Research 
Group 
Graft Design Model Results 
(Aguayo et al., 
1984) 
Combined PN grafts + 
mesencephalic fetal 
transplants 
6-OHDA lesioned rat 
model for Parkinson's 
disease 
Fetal mesencephalic neurons survived and extended long 
axons for about 2 cm along PN grafts inserted into the 
striatum 
(Gage et al., 
1985) 
Combined PN grafts + 
mesencephalic fetal 
transplants 
6-OHDA lesioned rat 
model for Parkinson's 
disease 
7/26 implanted rats showed 70% recovery of motor 
deficits with amphetamine-induced rotational behavior. 
DA neuron grafts survived in both behaviorally 
compensated and uncompensated rats; Neurites extended 




& Gash, 1990) 
Intrastriatal 
implantation of minced 
adrenal medulla 
combined + minced 




Monkeys receiving an implant of nerve only, exhibited 
survival of SCs and enhanced survival of adrenal cell 3 
months after implant surgery 
(Date et al., 
1996; Date et 
al., 1994) 
Intrastriatal co-graft of 
adrenal medulla + 
mouse sciatic nerve 
MPTP-treated mouse 
model of dopamine 
system depletion 
Immunocytochemistry indicated that co-grafts into the 
striatum significantly enhanced adrenal cell survival and 
tyrosine hydroxylase-positive host cells with a large 












+ PN co-grafted into 
the adjacent lateral 
ventricle 
6-OHDA lesioned rat 
model for Parkinson's 
disease 
Increase in density and area of reinnervation of the host 
striatum, with co-grafts clearly providing more extensive 
reinnervation  
(van Horne et 
al., 1991) 
Combined DA neurons 
grafts and minced 
sciatic nerve tissue 
6-OHDA rat model of 
Parkinson's disease 
Co-grafted animals exhibited significantly better 
functional recovery than animals receiving only DA 
neuron grafts 
(Watts et al., 
1997, 1995) 
Combined autologous 






Adrenal cell survival was good to excellent in the grafted 
striatum 
(Kohama et al., 
2001) 
Grafts of SCs cultured 





demyelination in rats 
Remyelination throughout the lesion with improved 
conduction velocity and action potentials conducted over 
a greater distance into the lesioned dorsal columns 
(Date et al., 
1995) 
Co-graft of adrenal 
medulla and PN into 





No postoperative complications with gradual and 
significant amelioration of the parkinsonian symptoms 









Table 1.2 (Continued) 
Clinical Trials 
(Date et al., 
1995, 1996) 
 Cograft of adrenal 
medulla and PN into 




(N = 1) 
No postoperative complications with gradual and 
significant amelioration of the parkinsonian symptoms 
starting 2 weeks and continued for 2 year after 
transplantation 











At two-year follow up, no morbidity was encountered. 
Motor test scores during the “off” state improved by 35% 
compared to baseline mainly in the side contralateral to 
the graft. 
(Timothy 
Vollmer et al, 
2011) 
Grafts of cultured 
autologous SCs in 




Reports from the funding agency state the surgical 
procedure was safe, with no adverse effects from the 
transplantation 
(van Horne et 
al., 2017; van 
Horne et al., 
2018) 
Combined DBS with 
autologous sural nerve 






Adverse event profiles were comparable to those of 
standard DBS surgery; UPDRS III motor scores suggest 
improvement at one year compared to baseline mainly on 
the side contralateral to the graft 
PN: Peripheral nerve graft; 6-OHDA: 6-hydroxydopamine; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; DA: 










Figure 1. 1 Reprogramming of Schwann cells into Repair Cells.  
 
After a nerve injury, distal SCs dedifferentiate, re-express precursor markers, alter their morphology, and migrate within 
regenerating tracks (Büngner bands). These tracks guide the regenerating axons back to their correct targets. Ephrin B expressed 
by the fibroblasts activates Eph receptor B2 on SCs to promote expression of cell junctions and extracellular matrix molecules. 
SCs crosstalk with the macrophages and interact with the released cytokines to activate different inflammatory pathways. The 
axonal debris and the myelin are cleared up by both the repair SCs and the macrophages to promote the regeneration of new 
axons. Pro-myelinating genes are downregulated through the cross-inhibition of Krox-20, POU domain class 3 transcription 
factor 1 (Pou3f1 or Oct-6), myelin protein zero (MPZ) and myelin basic protein (MBP) by c-Jun, Sox-2, Pax-3, Id2, and Egr1/3 
transcription factors. Repair SCs release various neurotrophic factors including NGF, BDNF, NT-3, NT-4/5, CNTF, trkB, trkA, 
GDNF, and Neuregulin. These factors induce neurite growth locally and are retrogradely transported towards the perikaryon to 









Figure 1. 2 Overview of DBS Plus Trial. 
 
Grafting of autologous peripheral nerve implants in the substantia nigra of a human subject 
with Parkinson’s disease. During Stage I surgery, a conditioning injury is introduced to the 
sensory sural nerve to activate the repair phenotype of the Schwann cells. The distal 
segment of the conditioned sural nerve, which contains the repair Schwann cells, is 
harvested after two weeks during the stage II surgery. The epineurium is removed, nerve 
fascicles are stripped and sectioned into petite segments and loaded into a custom-made 







CHAPTER TWO: MATERIALS AND METHODS 
 
Clinical Trial Design 
DBS Plus trial was designed as an open-label, single-center, Phase I clinical trial 
that aims to assess the safety and feasibility of grafting autologous peripheral nerve 
implants into the substantia nigra of patients with PD who were undergoing DBS surgery. 
The secondary outcome measure of this trial is the motor signs assessment after surgery in 
comparison to the baseline. The time frame is 24 months for participants who received 
single-unilateral implants, and 12 months for the group of participants who received double 
dose of the implants to the unilateral substantia nigra. The trial was registered with the 
ClinicalTrials. gov database (http://clinicaltrials.gov), and its registration number is 
NCT02369003. The study was reviewed and approved by the University of Kentucky IRB 
committee, and the informed consent was obtained from all participants. 
Participants Selection and Eligibility Criteria 
Participants who have met the criteria for DBS surgery had been selected, informed 
about the study, and consented for the DBS Plus the cell implantation procedure. Male and 
female participants who are 40 to 75 years show a positive response to Sinemet 
(Carbidopa/Levodopa), capable of tolerating the surgical procedure, and can follow up with 
their appointments were included in the study. Those who showed mild to moderate 





OFF and ON-medications, were done before the surgery, i.e., baselines scores. Participants 
who have any medical condition that would not make them a candidate for DBS of the 
STN or GPi or unable to give informed consent were excluded from the trial enrollment. 
Females who are pregnant, lactating, or of child-bearing potential and unwilling to use an 
adequate birth control method during the trial were also excluded from the study. 
PPMI Database for PD Control 
The data used for the PD Control group were obtained from the Parkinson's 
Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). PPMI is 
funded by the Michael J. Fox Foundation for Parkinson's Research and other funding 
partners (www.ppmi-info.org/fundingpartners). PPMI is a result of the collaboration of 
research centers of multiple sites around the word and biotechnology companies to find a 
biomarker of PD progression. Those centers have obtained approval from the local IRB 
committees and acquired consent from the participants. All observational data were then 
de-identified and shared on the PPMI database. The PPMI website details description of 
the PPMI methods in addition to the acquisition and dispensation of the data. The PPMI 
Data were downloaded in November 2019. The database included 2117 PD participants 
with a total of 14861 visits and an average of 7 visits per participant over a period of 6 
years. Our analysis was focused on three-time points: Baseline, 12 months from baseline, 
and 24 months from baseline. We aimed at refining the PPMI-control PD group to match 
the inclusion and exclusion criteria of the DBS-Plus trial with the baseline set at the time 





Subsequently, 80 participants from the PPMI Control PD database have matched the 
inclusion criteria and completed a 24-month visit after. 
Deep Brain Stimulation Plus PN Implantation  Surgery 
Deep Brain Stimulation (DBS) is a standard treatment for movement disorders such 
as Parkinson's disease, Essential Tremors, and Dystonia. Also, DBS was demonstrated to 
be effective in treating Epilepsy, obsessive-compulsive disorder, depression, and other 
neurocognitive disorders. By sending out electrical stimuli, DBS acts on several 
mechanisms to excite or inhibit different neuronal networks and modulate their synaptic 
transmission (Herrington, Cheng, & Eskandar, 2016). The downstream effects of electrical 
stimulation mainly depend on the chosen brain targets. The most common deep brain 
targets for treating PD are the subthalamic nucleus (STN), Globus Pallidus Internal (GPi), 
and caudal zona incerta nucleus(cZi). Those targets are carefully chosen with a 
multidisciplinary team of neurologists, neurophysiologists, psychologists, and a 
neurosurgeon to guarantee delivery of the best out symptomatic relief with a minimum side 
effect. Participants were evaluated before surgery using MRI. The trajectories and entry 
points of the DBS electrodes were mapped using Brainlab software (IPlan 3.0 Stereotaxy). 
The grafting trajectory was also mapped in parallel to that of the leads. The DBS surgery 
was done in two stages (van Horne et al., 2018).  
At stage I, the pulse generator was implanted, and lead extensions were projected 
from the chest to the skull. Next, the patient ankle was repositioned for a standard sural 
nerve biopsy incision. The sural nerve was exposed and transected about 10 cm between 





and two silk ties were secured distal to the transection for better identification of the nerve 
during stage II surgery. The incision was then closed in layers. The second stage of the 
DBS Plus was completed two weeks later. Coordinates of the targets and trajectories were 
calculated based on a fusion of the participants' CT scan and susceptibility-weighted 
images sequences of MRI for better and precise targeting. After implantation of the DBS 
electrodes, electrodes contacts were tested for efficacy and side effects. Once testing is 
completed, a second burr hole was drilled and a guide cannula (FHC Inc., 1.8-mm outer 
diameter) was then placed to target the Substantia Nigra contralateral to the most affected 
parkinsonian side of the patient. The previously transected sural nerve was prepared, and 
the distal stump of the nerve was identified. A 2-cm segment was harvested and rinsed with 
normal saline. The epineurium was delicately removed, and the fascicles were removed 
and dissected into five small segments of approximately 1 mm length. The segments were 
then loaded in the graft cannula, which was placed to target the SN (Figure 1.2). The graft 
cannula was then removed, and the dura was covered with the Durepair matrix from 
Medtronic. The bur hole was filled with HydroSet. This sequence of events was planned 
carefully not to intervene with the regular DBS procedure.  
The participants received MRI 24-48 hours post-operatively and a complete MDS-
UPDRS III assessment during their follow-ups. A total of 18 participants with idiopathic 
PD have consented for a bilateral DBS surgery targeting the GPi plus a single unilateral 
nerve implant targeted to the substantia nigra pars compacta. A total of 9 participants with 
idiopathic PD have consented for a bilateral DBS surgery targeting the GPi plus a unilateral 





Safety and Adverse Events Assessment  
Human participants were evaluated for long-term postoperative adverse events 
(AE). Clinical monitoring timepoints for this dissertation report includes perioperative time 
points, the 2-year evaluation visits for single and unilateral implanted participants, and 1-
year evaluation visits for participants who received double-unilateral implants. Through 
those time periods, AE was recorded from the clinical reporting, chart review, and specific 
queries during the clinical visits (van Horne et al., 2018). Postoperative 1.5-T MRI was 
used for evaluation 24-48 hours after the implantation surgery. AEs were classified into 
those which are related to DBS insertion or activation, graft-related procedure, or not 
related to both. AEs were also categorized in severity from mild to severe according to the 
Medical Dictionary for Regulatory Activities, version 11.0. 
Motor Assessment: MDS-Unified Parkinson's Disease Rating Scale Part III 
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (UPDRS) 
Part III is a standard clinical scale used to evaluate and assess the PD motor signs. The PD 
participants were examined and scaled by one of 3 neurologists who are specialized in 
movement disorders. Assessments were done in two states. During the OFF-medication 
State, participants were assessed and scored after being off Levodopa-Carbidopa or any 
other PD medications for about 12 hours. Then, participants were allowed to take their 
prescribed Levodopa-Carbidopa dose, and they were re-assessed 1-2 hours afterward (State 
2: ON-medication score). All post-op assessments are done with DBS stimulation being 





UPDRS Part III is made of 18 items. Each subscale has 0-4 ratings, where 0 = normal, 1 = 
slight, 2 = mild, 3 = moderate, and 4 = severe.  
Tissue Collection for translational studies 
Experimental procedures, including handling and implanting human peripheral 
tissue, were reviewed and approved by the IRB of the University of Kentucky. Sural nerve 
fascicles were obtained from living adult participants with PD (aged 45-70 years). The 
donors had no known diagnosis of peripheral nerve pathologies or neurological illness 
other than PD. The sural nerve samples were collected in two stages: Stage I was followed 
by Stage II two weeks later. The sural nerves were dissected, and the nerve fascicles were 
collected on average 30 and 60 minutes after harvesting from stage I and stage II surgeries, 
respectively. Human peripheral nerve fascicles were obtained from 6 human subjects 
undergoing DBS-Plus surgery for Parkinson's disease for RNA sequencing studies. For the 
Neuro-Avatar experiments, human peripheral nerve fascicles, collected from both stage I 
and stage II surgeries, were obtained from 4 human subjects undergoing DBS-Plus. The 
removed section of the nerve was then stripped of its epineurium using microsurgical 
dissection in cold, sterile saline. Individual fascicles of nerve fibers were separated using 
jeweler's forceps, and the perineurium was discarded. These fascicles were placed in 
conical micro-centrifuge tubes, snap-frozen on dry ice, and stored at -80°C until they were 
assayed using RNA sequencing technique. The nerve fascicles that were collected for the 
in vivo experiments, Neuro-Avatar, the fascicles were collected in sterile conditions, 







RNA isolation was performed by homogenizing sural nerve fascicles in 1ml of TRI 
Reagent Solution (ThermoFisher AM9738) using a Fisher Scientific Power Gen 35 
homogenizer with a microtip homogenizing probe. The homogenized lysate was 
transferred to a pre-pelleted 5Prime Phase Lock Gel – Heavy 2 mL tube (ThermoFisher 
NC1093153) and incubated at room temperature for 5 minutes. 200µl of chloroform was 
added, and the tube was shaken vigorously by hand for 15 seconds. Phase separation was 
performed by microcentrifugation at 12,000 x g for 10 minutes. The RNA containing 
aqueous phase was taken from the top of the Phase Lock Gel layer and transferred to a 1.7 
mL microfuge tube. RNA was precipitated by adding 0.5 ml isopropyl alcohol, mixed by 
repeated inversion, and incubated at room temperature for 10 minutes. RNA was pelleted 
by microcentrifugation at 12,000 x g for 10 minutes at 4°C. The RNA pellet was washed 
two times, with 80% ethanol using a 7,500 x g microcentrifugation for 5 minutes at 4°C to 
pellet RNA between washes. RNA pellets were air-dried 5-10 minutes at room temperature 
and resuspended in 25µl of nuclease-free water. RNA purity was assessed by 
OD260/OD280 ratio calculation using a ThermoFisher NanoDrop 1000. RNA integrity 
was assessed by Agilent Bioanalyzer 2100 using the Eukaryotic Total RNA Nano assay.   
RNA sequencing 
RNA-Seq was performed at a strand-specific 100 cycle paired-end resolution in an 
Illumina HiSeq 2500 sequencing machine (Illumina, San Diego, CA). In a repeated 





lesioning; thus, resulting in a total of 12 samples. The 12 samples were multiplexed in two 
lanes of a flow-cell, resulting in between 25 and 34 million reads per sample. The read 
quality was assessed using the FastQC software (Andrew S. 2010). On average, the per 
sequence quality score measured in the Phred quality scale was above 30 for all the 
samples. The reads were mapped to the human genome (GRCh38) using the STAR 
software version 2.3.1z (Dobin et al., 2013). On average, 96.4% of the sequenced reads 
mapped to the genome, resulting between 24.3 and 32.8 million mapped reads per sample, 
of which, on average, 89% were uniquely mapped reads. Transcript abundance estimates 
were calculated using HTSeq (version 0.6.1) (Anders  S et al. 2015). Expression 
normalization and differential gene expression calculations were performed in edgeR 
(release 2.14) (Robinson & Oshlack, 2010) to identify statistically significant differentially 
expressed genes. A paired sample design was used in edgeR, which employs a negative 
binomial generalized linear model (NB-GLM) for statistical calculations. The edgeR 
package implements advanced empirical Bayes methods to estimate gene-specific 
biological variation under minimal levels of biological replication. The RNA composition 
in each sample was normalized in edgeR using the trimmed mean of M-values (TMM) 
method. The significance p-values were adjusted for multiple hypotheses testing by the 
Benjamini and Hochberg methods and as modified by Storey (Benjamini & Yekutieli, 
2005) providing a false discovery rate “q-value” for each differentially-expressed gene. 







RNA-seq data were organized in a Microsoft Excel table for subsequent analyses. 
These normalized read counts (counts per million- CPM) were used to calculate fold-
change between the pre-lesion and post-lesion samples, and the Log base 2 of fold change 
was used for further analysis. Correlation matrices between different differentially 
expressed transcription factors, and the respective genes were generated in JMP Pro 14 
software. AmiGO Gene Ontology (GO) annotations (http://www.geneontology.org/) for 
pathways of interest were cross-referenced with significantly differentially expressed 
genes, yielding a list of differentially expressed genes related to each GO annotation's 
respective biological function. The GO annotations chosen to be visualized in heat maps 
were selected based on their relevance to peripheral nerve repair.16 Statistical criteria of q 
<= 0.05 and |FC|>= 2 were selected, yielding a total of 3,641 differentially expressed genes 
included in this analysis. Heat maps of the qualifying genes were generated using JMP Pro 
14 (SAS). When applicable, hierarchical clustering was performed using Ward's method in 
JMP.  
Animal Care 
All animal procedures were approved by the IACUC of the University of Kentucky 
and were performed in accordance with the NIH guidelines for the care and use of 
laboratory animals. Twenty-three adult male athymic nude rats (weigh 100-450 g; Charles 
River Laboratories, Chicago, IL) were housed in micro-isolated cages and kept in a sterile 





Cages and bedding were changed every three days. Clinical observations, as well as health 
and mortality records, were noted. 
Implantation of Human Peripheral Neve in Neuro-Avatar 
Young (4-8 weeks old) athymic nude rats (NIH-Foxn1rnu) were anesthetized under 
isoflurane and received implants of human nerve fascicles into the dorsal striatum. A total 
of 16 animals received nerve grafts (8 of stage I and 8 of stage II nerve fascicles). Half of 
each animal group was randomly selected for brain collection and histological analysis at 
two weeks, while the other half were euthanized at 6-month post-implantation. One mm3 
of human nerve fascicle was delivered over 4 minutes using a 23-gauge adjusted needle 
with a personal style and directed at the following stereotaxic coordinate within the 
striatum: AP: +1.0mm, ML: -3.0 mm, DV: -5.0 mm. After implant deployment, a 4-minute 
wait period was maintained to allow attachment of the implant to the host brain tissue, the 
skin wound was stapled, and the animal was allowed to recover from anesthesia. 
Histological Procedures 
At the endpoints (two weeks and six months) post-transplantation, animals were 
deeply anesthetized using a single dose of pentobarbital (100 mg/kg IP) and transcardially 
perfused with 250 mL of normal cold saline followed by 180 mL of 4% Paraformaldehyde 
(PFA). The brain was extracted and postfixed with 4% PFA for at least 24 hours. Following 
post-fixation, the implantation site was identified and cut into a 1 cm section in brain mold 
and cryoprotected in 30% sucrose for three days. Cryopreserved brains were cut coronally 






To identify the transplanted human peripheral nerve cells and examine their 
interaction with the host CNS, immunostaining with antibodies against Human Nuclear 
Antigen (HNA) was employed. Tissue series from the grafted brain sections were subjected 
to the Anti-HNA antibody together with DAPI (4′,6-diamidino-2-phenylindole). The 
primary antibody used was Mouse Anti-human HNA (1:500; Catalog#: ab191181, Abcam, 
Cambridge, MA). The fluorescent secondary antibody was Alexa conjugated goat Anti-
mouse IgG (1:500; Catalog#: ab150113, Abcam, Cambridge, MA). To ensure the 
specificity of observed immunostaining, both positive and negative controls were included 
during staining. Negative controls consisted of the incubation of the primary or secondary 
antibodies alone, in addition to a non-grafted and intact rodent brain collected after six 
months of the experiment. Positive Controls consisted of incubation of sections of human 
sural nerve collected during both stage I and stage II surgeries. The brain sections were 
transferred from their wells and washed once with PBS. The tissue was permeabilized 
using 0.2% Triton X-100 for 5 minutes and then washed with PBS once. The slides were 
blocked with 5% goat serum, 1%Triton X-100 for 1 hour. Afterward, the slides were 
incubated with the primary antibody in PBS, 0.1% goat serum overnight at 4'C. The next 
day, the slides were washed with PBS, 3x5 minutes, and incubated with fluorescence-
conjugated secondary antibody in PBS, 0.1% normal serum for 1-2 hours at RT in the dark. 






Magnetic Resonance Spectroscopy 
Magnetic Resonance Spectroscopy is possible on any nucleus producing a magnetic 
moment. The metabolically active proton nuclei (1H) is the most sensitive for NMR, and 
it allows us to detect a large number of important amino acids and metabolic pathways' end 
products like N-acetyl aspartate (NAA) and Creatine (Cr) /phosphocreatine. In healthy 
brain tissue, the most prevalent resonance originates from the methyl group of NAA at 2.02 
ppm (Moffett et al., 2007). The chemical shifts are referenced in regards to that of 3-
(trimethylsilyl)1-propane sulfonic acid at 0.00 ppm. NAA is exclusively localized in the 
CNS as well as the PNS. NAA has been used as a marker for viable neurons as it is only 
found in neurons, and its concentration decreases in the neurodegenerative diseases which 
affect the CNS (Schuff et al., 2006). The NAA concentration is yet not uniform and varies 
between gray matter (8-11 mM) and white matter (6-9 mM) (Moffett, Arun, Ariyannur, & 
Namboodiri, 2013; Moffett & Namboodiri, 1995). The methyl and methylene protons of 
creatine and phosphocreatine resonate at 3.03 ppm and 3.93 ppm. Since the sum of both 
forms, total creatine (tCr), is constant in adulthood, the later can be used as a suitable in 
vivo concentration reference. Glutamate and Glutamine peaks were determined at 2.1-2.5 
ppm and 3.7 ppm, respectively. Brain morphology and metabolism were assessed using 
T2WI magnetic resonance and imaging MRI and MRS (7-tesla Horizontal bore magnet; 
Bruker/Siemens scanner) at three months post-implantation in Neuro-Avatar animals. Two 
animals were used for MRS studies at three months post-implantation. The first one was a 
neuro-avatar athymic rat that has received a stage II human nerve implants into the right 
dorsal striatum. The second animal was a sham animal where a cannula with PBS, and no 





isoflurane. The heads of the rats were fixed in a body retainer, the respiratory rate was 
monitored, and the body temperature was maintained at 37 oC with a body heating pad. 
The spectra were acquired at TR/TE/NS=2500/3/200 for ipsilateral as well as the 
contralateral striatum with the voxel (volume = 3×2×3 mm3) placed just next to the graft 
trajectory. Ipsilateral metabolic concentrations were normalized to the contralateral (intact) 
ones before comparing the two treatment groups. 
Thesis Outline 
The following chapters investigate the use of peripheral nerve implants in 
combination with DBS to alter the disease progression of PD. Peripheral nerves have a 
remarkable potential for repair and regeneration in response to an injury compared to the 
CNS (Gu et al. 2014, Sheng Yi et al., 2018). Schwann cells, within the distal stump of the 
injured nerve, play a major role in promoting and maintaining axons regeneration from the 
proximal stump. Those cells release neurotrophic factors and cross-talk with the basal 
lamina, fibroblasts, and immune cells to ensure adequate regeneration. In our first study, 
we analyzed, using high throughput RNAseq analysis, the impact of the conditioning 
transectional injury on human sural nerve's molecular pathways at 14 days following the 
injury. Our main goal was to validate if the nerve implants collected from participants with 
PD will contain the repair molecules that are required to induce neuroprotection and axons 
regeneration of the degenerating nigrostriatal system. 
In Chapter Four, we studied the viability and trophic effect of the nerve implants 
after being implanted in the CNS. Pre-lesion and post-lesion sural nerve implants were 





athymic and immunodeficient rats. Immunostaining for human Schwann cells at six 
months post-implantation (longest period examined) demonstrated the ability of those cells 
to tolerate the grafting procedure and to survive the central nervous environment. 
Furthermore, stage II (14 days post-lesioning) nerve implants contained a higher load of 
cells and were able to survive better up to 6 months post-implantation when compared to 
Stage I (pre-lesion) nerve implants. Additionally, the brain tissue reaction to the human 
nerve implants was evaluated using in vivo magnetic resonance spectroscopy  
In Chapter Five, we examined the safety and efficacy of combining DBS surgery 
with autologous nerve implant stereotactically targeted to the substantia nigra of human 
subjects with PD. In this study, two treatment groups of participants were studied. The first 
is a group of 16 human subjects who received a single and unilateral dose of nerve implant 
while in the second group, nine human subjects with PD have received a double-unilateral 
dose of nerve implants. The participants were followed up to 24 months after the surgery. 
The adverse events reported by both study groups were similar to those of DBS surgery. 
On the other hand, the clinical motor assessments indicated an improvement in UPDRS III 
scores up to two-years after-grafting. The post-hoc analysis demonstrated that the 
improvement in the parkinsonian signs was mostly lateralized to the side contralateral to 
the implanted substantia nigra. Finally, we discuss how the combination of Deep Brain 
Stimulation Surgery and autologous peripheral nerve implantation could be a safe and 





CHAPTER THREE: TRANSCRIPTOME ANALYSIS OF IN VIVO 
PREDEGENERATED PERIPHERAL NERVE  
 
Abstract 
The development of regenerative therapies for central nervous system diseases can 
likely benefit from an understanding of the peripheral nervous system repair process, 
particularly in identifying potential gene pathways involved in human nerve repair. This 
study employed RNA sequencing technology (RNA-seq) to analyze the whole 
transcriptome profile of the human peripheral nerve in response to an injury. The distal 
sural nerve was exposed, wholly transected, and a 1-2 cm section of nerve fascicles were 
collected for RNA-seq from six participants with Parkinson’s disease, ranging in age 
between 53 and 70 years old. Two weeks after the initial injury, another section of the 
nerve fascicles of the distal and pre-degenerated stump of the nerve were dissected and 
processed for RNA-seq studies. An initial analysis between the pre-lesion status and the 
post-injury gene expression revealed 3,641 genes that were significantly differentially 
expressed. Our results provide evidence for the trans-differentiation process that occurred 
by the end of the 2-weeks post-injury. Gene ontology and hierarchical clustering were used 
to identify the major signaling pathways affected by the injury. In contrast to previous non-
clinical studies, substantial changes were observed in molecular pathways related to glial 
cell proliferation, neurotrophic factors release, Axonogenesis, neural synaptic plasticity, 





the essential interactions of different molecular pathways that drive neuronal repair and 
axonal regeneration in humans.  
Introduction 
Peripheral nerves have a spectacular capacity for regeneration in comparison to the 
CNS (Scheib & Höke, 2013). Regardless of the type of the injury, the distal stump of the 
peripheral nerve initiates an orchestrated pattern of complex cellular and molecular events 
leading to proximal neuron survival and axon regeneration towards the original target. This 
series of events, which have been known as Wallerian degeneration, take place over mainly 
two stages (K. Jessen & Mirsky, 2016). The early-stage happens within the first five days, 
and the later stage occurs 1-2 weeks after injury. During the early stage, the axonal debris 
and myelin are cleared by SCs and the invading immune cells followed by morphological 
changes of the SCs to facilitate their migration and formation of the regenerative tracks 
(Bands of Büngner). Promotion of the Axonogenesis and neuronal repair occurs mainly 
during the later stage. This regenerative capacity of the peripheral nerve highly depends on 
genetic changes driving adequate SCs-axon interaction, appropriate immune cells’ 
response, and suitable release of neurokines, chemokines, and growth factors. Trophic 
factors such as GDNF, NGF, the FGFs, neurotrophin-3 (NT-3), BDNF, PDGF, interleukin-
1, and apolipoprotein E, facilitate SC and neuronal survival, axonal elongation as well as 
an anti-inflammatory response for  (review see (Li et al., 2020)). Moreover, the adequate 
delivery of cytokines, including tumor necrosis factor α (TNFα), tumor growth factor β 





cascades and production of chondroitin sulfate proteoglycans (CSPGs) which can impede 
neuronal survival and axonal outgrowth (K. Jessen & Mirsky, 2016). 
Identification of the genes involved in peripheral nerve regeneration and how they 
interact is crucial to exploring strategies that enhance the neural protection, regeneration, 
and repair processes. On the other hand, promoting successful regeneration in CNS has 
been difficult in neurodegenerative diseases, traumatic brain injury, stroke, epilepsy, and 
PD. Yet, understanding the gene expression changes that drive effective neural repair 
within the PNS may also help in identifying new therapeutic targets or methods that could 
enhance CNS neural regeneration. 
Whole-transcriptome profiling of gene expression in response to peripheral nerve 
injury can now be feasibly studied using RNA sequencing (RNA-seq) technology. RNA-
seq combines molecular biology approaches of RNA amplification with bioinformatics 
tools for measuring and validating large RNA sequencing datasets. This technique allows 
for quantitative measurements of thousands of gene transcripts using small (10-30 mg or 
less) quantities of tissue (for reviewing the applications of RNA-seq see (Han, Vickers, 
Samuels, & Guo, 2015)). The study reported herein presents the analysis of the 
transcriptome profile of in vivo predegenerated sural nerve tissue in patients with PD and 
to help evaluate how a conditioning injury of peripheral nerve tissue can induce pro-
regenerative changes. 
Our study was conducted in conjunction with an ongoing clinical trial 
(clinicaltrials.gov:NCT#02369003;https://clinicaltrials.gov/ct2/show/NCT02369003?term
=NCT02369003&cond=Parkinson+Disease&draw=2&rank=1), the “DBS Plus” trial, 





Parkinson’s disease (PD) at the time of deep brain stimulation (DBS) surgery. To our 
knowledge, this study is the first of its type studying and analyzing the human peripheral 
nerve genetics in response to a transection injury within the same human subjects. The trial 
involved a collection of two samples of the sural nerve from the same participants at two 
distinct time points. The first sample, referred to as the “pre-lesion” sample, was collected 
from the participant’s sural nerve during Stage I of the surgery, which involved DBS 
hardware implantation. The second sample, referred to as the “post-lesion” sample, was 
taken two weeks later from the distal end of the same nerve during Stage II of the surgery, 
which is the stage when the DBS leads are positioned into the STN or GPi nuclei. This 
two-stage approach corresponded with the two stages of DBS surgery and was designed to 
induce pro-regenerative changes in the peripheral nerve following an injury (van Horne et 
al., 2017).  
In our current study, we hypothesize that pre-conditioned implants harvested from 
the distal stump of the sural nerve in participants undergoing the stage II of DBS Plus, 14 
days post-lesioning, will hold a transcriptional profile that promotes nerve regeneration 





The nerve samples were collected from human participants with PD who electively 
participated in the clinical trial testing the safety and feasibility of peripheral nerve implants 
to the CNS for the treatment of PD. The nerves samples of 6 participants, (two females, 





The study was approved by the University of Kentucky institutional review board, and 
informed consent was obtained from all study participants. 
 
RNA Collection and Sequencing 
 
 
RNA collection and sequencing were done as described in the Methods section of 
Chapter Two. In a repeated measure design, mRNA from the six individual samples were 
sequenced pre and post lesioning; thus, resulting in a total of 12 samples. These normalized 
read counts (counts per million- CPM) were used to calculate fold-change between the pre-
lesion and post-lesion samples, and the log base 2 of fold change (log2FC) was used for 
further analysis. Genes with an absolute fold difference ≥ 2 and q ≤ 0.05 were considered 
statistically significant, yielding a total of 3,641 differentially expressed genes included in 
this analysis. AmiGO Gene Ontology (GO) annotations (http://www.geneontology.org/) 
for terms of interest were cross-referenced with significantly differentially expressed 
genes, yielding a list of differentially expressed genes related to each GO annotation’s 
respective biological function. Heat maps of the qualifying genes were generated using 
JMP Pro 14. Hierarchical clustering was performed using Ward’s method in JMP.  
Results 
Nerve Tissue Collection 
The mass and freezing delay time (time from when the nerve was harvested from 
the participant to when it was snap-frozen in dry ice) were calculated for the nerve tissue 





significantly longer (p-value= 0.0022, Figure 3) at Stage II (two weeks after injury) (59 ± 
25 min; Mean ± SD) compared to Stage I (Intact state) (18 ± 5 min). This difference was 
a result of the longer technical surgical procedures needed for the clinical trial during 
Stage II of the DBS surgery. The mitigation of Mass Effect during the RNA Access 
library prep is accomplished in multiple ways through normalizations incorporated at 
multiple steps through the entire process of library prep and sequencing. 
Glial Cell Proliferation 
Figure 3.2 shows all significantly differentially expressed gene transcripts 
annotated with the GO term “Positive Regulation of Glial Cell Proliferation” 
(GO:0060252) in Homosapiens. Out of 19 unique genes with this GO annotation, 6 of those 
genes (IL1B, LYN, E2F1, PRKCH, MYB, IL6) were significantly differentially expressed 
while only one gene (PLAG1) appeared to be less expressed 14 days after the initial nerve 
transection injury. On the other hand, 7 genes (IDH2, CERS2, SOX10, DICER1, PTN, 
HES1, ADCYAP1R1) out of 16 genes associated with “Negative regulation of glial cell 
proliferation” (GO:0060253) were differentially significantly expressed. 
Growth Factor Activity 
Figure 3.3 shows all significantly differentially expressed (q< 0.05, |FC|>2) gene 
transcripts annotated with the Gene Ontology (GO) term “Growth Factor Activity” 
(GO:0008083). Out of 166 unique genes with this GO annotation, 43 (25.9%) were 





Stage II). Twenty-six of those genes were enriched in the predegenerated nerve tissue in 
comparison to normal levels while 17 genes were less abundant 
Regulation of Axons Regeneration and Extension 
 Out of 96 genes associated with gene ontologies: “Regulation of Axon Extension”-
(GO: 0050772) and “Axon Regeneration” (GO: 0045773), 12 genes were significantly 
upregulated in the distal nerve tissue after injury in comparison to their initial transcript 
levels which were sequenced and measured in the sural neve samples collected during stage 
I surgery (Figure 3.4). The expressed genes included PLXNC1, SCARF1, HGF, BDNF, 
NRP1, FKBP1A, GRN, LIMK1, FN1, HCLS1, TRPV2, and TNFRSF12A. On the other 
hand, 12 genes were transcribed at significantly lower levels two weeks after the initial 
conditioning injury to the sural nerve during stage I surgery. 
Regulation of Neural Synaptic Plasticity 
All five human genes associated with the gene ontology term “Positive Regulation 
of Neural Synaptic Plasticity” (GO:0048170) demonstrated higher transcript levels in the 
distal nerve tissue harvested during stage II surgery in comparison to that from stage I 
surgery (Figure 3.5). Of particular interest, SHANK3 and KIT genes were significantly 






Associated Transcription Regulatory Factors  
624 unique transcription factors (TFs) with regulatory functions related to the 26 
growth activity-associated genes, which were significantly upregulated (figure 3.2), were 
identified based on the Genecards database (a repository of a database for human gene and 
proteins with links to other databases https://www.genecards.org/). 267 TFs were 
differentially and significantly between stage I and Stage II with p or q values ≤ 0.05 and 
|FC| ≥ 2. Yet, only 38 TFs (figure 3.3) were differentially expressed and with an expression 
profile that is significantly correlated (|Pearson correlation| ≥ 0.8) to the expression trends 
of the growth factors. The correlation matrixes were calculated and plotted by JMP Pro14 
software. Out of the total 38 TFs, 31 TFs were significantly expressed and had a strong 
positive correlation of expression with at least one of 21 Growth factors. On the other hand, 
22 TFs were significantly downregulated after injury, while their expression profile had a 
significant and strong negative correlation with at least one out of 18 Growth factors (figure 
3.6). Of particular interest was the downregulation of AHR transcription factor (FC= -
2.023) while its downregulation was significantly correlated to the upregulation of GDNF 
(FC=3.54, Correlation = -0.98, and p-value = 0.0006). 
Transcriptome Profile of PD-Related Genes 
Mutations in more than 20 genes have been identified and linked to Parkinson’s 
disease. The hallmark pathology of PD is the deposition of Lewy bodies within the 
dopaminergic neurons. Lewy bodies are protein aggregates consisting of different proteins, 





synucleinopathies; other synucleinopathies include multiple system atrophy and Lewy 
body dementia, which clinically overlap with PD (Cornelis Blauwendraat et al. , 2020). We 
were interested in studying the expression of SNCA and other PD-related genes in the 
peripheral nervous system of patients with PD and how their transcriptomic profile would 
change in response to an injury. Differential expression analysis of RNA transcripts-count 
per million (CPM) values using p < 0.05, FDR < 0.05, and |Log2FC| ≥ 1 as cutoff criteria 
produced a total of 8 transcripts differentially expressed between intact nerve tissue (stage 
I) and post-injury profile (stage II). Among these differentially expressed genes, seven 
transcripts (SNCA, LRRK2, PLA2G6, DNAJC6, MAPT, SIPA1L2, and PDZRN4) were 
downregulated and only one (GCH1) was upregulated two weeks after nerve injury (figure 
3.7a, 3.7b). Of particular note, SNCA gene transcript was significantly downregulated 
(Log2FC = -2.5, p-value=1.5E-18, FDR=2.49E-17).  
To further study the molecular signaling that might have played a role in the 
downregulation of those PD-related genes, we identified through the Reactome database a 
total of 103 candidate transcription factors (TFs). Those TFs were either directly or 
indirectly correlated to the signaling pathways involved in the expression of PD-related 
genes. Only 25% of those TFs were differentially expressed after injury, and their 
transcriptomic profiles were significantly correlated to the expression of the PD-related 
genes with a cutoff threshold of |Pearson’s correlation| ≥ 0.8, and p-value < 0.05 (figure 
3.8). 7 TFs (SMARCA4, TFDP1, XRCC5, ZNF792, MAZ, SOX13, and DRAP1) were 
identified as potential repressors of 5 PD-related genes (SNCA, MCC1, LRRK2, 
PARK2, and DNAJC6). The expressions of those TFs were upregulated and significantly 





repressors for SNCA gene expression were identified: ZNF792 and DRAP1. On the other 
hand, 17 potential enhancers were identified and positively correlated to the expression of 
7 PD-related genes (SNCA, LRRK2, PDZRN4, DNAJC6, MCCC1, PARK2, and PINK1). 
Discussion 
In this study, we present the relevant transcriptome of human sural nerve tissue and 
characterize transcriptional changes at 14 days following a transectional injury. We provide 
evidence that the transection lesion paradigm used in the DBS Plus surgeries induces 
phenotypic changes in the peripheral nerve tissue consistent with the peripheral nerve 
repair response: immune cell infiltration plus cell proliferation, Wallerian degeneration of 
axons, and up-regulation of growth factors production (Arthur-Farraj et al., 2012; Arthur-
Farraj et al., 2017; Cattin & Lloyd, 2016; K. R. Jessen & Arthur‐Farraj, 2019). Our 
experimental design included harvesting sural nerve tissue from 6 human subjects who 
were undergoing DBS surgery for PD. The mRNA from a total of 12 individual samples 
were sequenced and measured pre and post lesioning using RNA Sequencing technique. 
Normalized read counts (CPM) were used to calculate fold-change between the pre-lesion 
and post-lesion samples, and Log2FC was used for further analysis. Genes with an absolute 
fold difference ≥ 2, p ≤ 0.05, and FDR ≤ 0.05 were considered statistically significant, 
yielding a total of 3,641 differentially expressed genes. AmiGO Gene Ontology (GO) 
annotations for specific signaling pathways were cross-referenced with significantly 
differentially expressed genes, yielding a list of differentially expressed genes related to 





A large number of differentially expressed genes were identified, most of which 
were involved in growth factor activity, glial cell proliferation, axon regeneration and 
extension, and positive regulation of neural synaptic plasticity, based on Gene Ontology. 
To better refine the results of our RNA-seq analysis to a more “biologically relevant” 
dataset, we decided to limit our observations to the genes whose transcript levels exceeded 
a fold change threshold of |FC|>2. However, this convention might have excluded genes 
that were biologically relevant at lower fold changes. For example, the transcription of NF2 
gene, a marker of Schwann Cell proliferation, was statistically significantly increased (p-
value =0.0192). However, the fold change of transcript levels was less than 2, so it was not 
included in the visualized data. Likewise, Mesencephalic Astrocyte Derived Neurotrophic 
Factor (MANF) transcripts level was significantly higher post-injury (p-value= 3.03E-07), 
yet its FC was 1.754 (data not shown). MANF plays a vital role in different reparative 
phases during the neuronal regeneration processes, and MANF therapeutics are expected 
to enter clinical trials (Sousa-Victor, Jasper, & Neves, 2018). Furthermore, we focused in 
this paper only on transcripts that were differentially expressed between pre- and post-
lesion samples while recognizing that some genes could be highly expressed in both stages, 
but not necessarily differentially. That could be one limitation of this broad analysis 
approach, and in the specific case of NF2 levels in this tissue merits further study.  
The gene cluster of the growth factor terms showed multiple differentially 
expressed genes, with the majority being increased. One increased gene of note is GDNF, 
which is neuroprotective and neurorestorative of dopaminergic neurons and has been tried 
as a therapeutic intervention for PD in preclinical and clinical studies (Quintino et al., 2019; 





demonstrated an upregulation of GDNF transcription. Only the nerve sample collected 
from participant number 2 showed a lower number of GDNF transcripts after injury (Figure 
3.3). The significant longer freezing time delay for this sample (Table 1) might have 
negatively affected GDNF-mRNA stability and its relevant count during RNAseq 
processing. Multiple interleukins were also upregulated, which, in addition to being 
cytokines, play a role in neurogenesis (Borsini, Zunszain, Thuret, & Pariante, 2015).For 
example, the levels of gene transcript for IL-6, which has been described as neuroprotective 
against focal brain injury, were increased in response to the nerve injury (Penkowa et al., 
2003). The growth factor activity genes, which were decreased (for example, CDNF) at 
two weeks post-injury, are also of interest and may indicate the complexity of the neuronal 
repair process in regard to the changes of individual growth factors over time in response 
to nerve injury. That was evident in the work of Lin et al., 2019 as PPAR, PI3K-Akt, and 
chemokine signaling pathways were dominant in early Wallerian degeneration (Lin, Xie, 
Zhou, Yin, & Lin, 2019). Whereas at the later stage, the main signaling pathways were 
ErbB, tumor necrosis factor, AMPK, MAPK, PPAR, and Wnt. 
To our knowledge, this is the first report to publish data about the transcriptional 
regulators and the enriched growth factors after human peripheral nerve injury. Over 600 
transcription factors potentially related to the expression of upregulated growth factors 
were generated through Reactome libraries (http://www.reactome.org/). Only 38 
transcription regulators were differentially expressed and significantly correlated in the 
upregulation of 24 growth factors, which were upregulated (figure 3.6). These findings 
substantially add to our understanding of the signaling pathways which intervene in 





aryl hydrocarbon receptor (AHR) may act as a potential repressor of GDNF expression. 
Previous studies have shown that knocking out AHR upregulated vascular endothelial 
growth factor (VEGF) expression and markedly enhanced the ischemia-induced 
angiogenesis (Ichihara et al., 2019). Hence, inhibiting AHR may enhance GDNF synthesis 
after injury. 
We have previously demonstrated the upregulation of several genetic pathways 
involved in trans-differentiation and reprogramming of Schwann cells into “repair” cells 
in response to nerve injury to humans (Welleford et al., 2019). Nonetheless, the current 
transcriptome analysis adds to our understanding of the reprogramming process of those 
cells through mapping the expression of essential regulatory genes that are clustered to the 
proliferation of those glial cells (figure 3.2). The transcript levels of 8 of those genes were 
enriched (E2F1, IL1B, IL6, LYN, MYB, PRKCH, IDH2, and ADCYAP1R1) while the 
expression of only 2 genes (SOX10, PLAG1) was significantly downregulated at 2 weeks 
post-injury. The later genes were clustered as negative regulators of Schwann cells 
proliferation (Fujiwara et al., 2014); thus, repressing their expression may have helped to 
induce the proliferation  of Schwann cells. Furthermore, several genes were significantly 
expressed and involved in axonogenesis, axons regeneration and extensions, and enhancing 
neural synaptic plasticity such as PLXNC1 (Chabrat et al., 2017), GRN (Rosen et al., 
2011), and SHANK3 (Huang et al., 2019) (figure 3.4, figure 3.5). 
PD is a progressive neurodegenerative disease accompanied by the degeneration of 
dopaminergic neurons within the substantia nigra of the midbrain. Approximately 10% of 
the PD cases are familial with a spectrum of PD-causative genes that have been identified 





of the major PD-related mendelian genes and the PD-risk loci (Hernandez, Reed, & 
Singleton, 2016). A total of 8 PD-related genes (SNCA, DNAJC6, PLA2G6, LRRK2, 
PDZRN4, SIPA1L2, MAPT, and GCH1) were differentially expressed. Most importantly 
was the consistent downregulation of alpha-synuclein (SNCA) gene among the 6 subjects 
(FC = -5.56, p =1.5 E-18, FDR = 2.5E-17). At least 30 mutations in the SNCA gene have 
been found to cause PD. Two main types of alterations of the SNCA gene are related to PD 
(Petrucci, Ginevrino, & Valente, 2016). In one mutation, the amino acid alanine is replaced 
with threonine at protein position 53 or with the amino acid proline at position 30. These 
mutations cause the alpha-synuclein protein to be misfolded and hazardously aggregates in 
the cells. In the other type of alteration, SNCA gene is inappropriately duplicated or 
triplicated, leading to an excess of alpha-synuclein deposition in patients with PD (Zafar et 
al., 2018). It is unclear how SCNA gene causes PD, but alpha-synuclein proteins cluster 
together to form Lewy bodies leading to selective death or impairment of neurons that 
produce dopamine. There is evidence that inhibition of α-synuclein aggregation can 
improve the survival of neurons after injury (Teil et al., 2020). To our knowledge, eight 
transcription factors have been demonstrated to be involved in regulating SNCA 
transcription. GATA2 and p53 promote SNCA transcription; PARP1, EMX, C/EBPβ, and 
NKX6/1 repress it while ZSCAN21 and ZFN210 can have both effects; for review see 
(Piper, Sastre, & Schüle, 2018). To further explore the signaling pathways involved in the 
expression SNCA and the other PD-related gene in Stage II nerve samples, hundreds of 
unique regulatory transcription factors were functionally mapped to be Parkinson’s related 
genes through Reactome pathway database. 20 transcription factors were differentially 





factors (EGR2, NBN, ZXDB, NRF1, ZNF792, ZBTB20, ZFHX2, and DRAP1) were 
significantly correlated to the downregulation of SNCA expression. In particular, the 
upregulation of ZNF792 (FC = 2.0, p =4.6E-6, FDR =1.8E-5) was significantly correlated 
(r = -0.837, p = 0.037) to the repression of SNCA gene in stage II. This finding strongly 
points to ZNF792 as a potential repressor of SNCA gene. Future studies using gene therapy 
to target such repressors of SNCA may help reduce alpha-synuclein aggregation in the 
neurons (Valente et al., 2020). 
Conclusion 
In summary, this study provides evidence that the sural nerve autologous implants, 
which are harvested from PD participants two weeks after a conditioning injury, embrace 
a repair phenotype consistent with a release of growth factors, a proliferation of Schwann 
cells, axons regeneration, and enhancement of neural synaptic plasticity. We have also 
demonstrated significant changes in several major PD-associated genes. We have 
identified novel transcription regulators of several PD-associated genes, like SNCA, which 
will expand our knowledge about the different molecular pathways involved in the 
regulation of PD-causative genes. We believe that this transcriptomic analysis will be of 







Table 3. 1 Mass and Freezing Time Delay of the nerve samples collected during Stage I 
vs. Stage II. 
 
 
 STAGE I SAMPLES 
 
 STAGE II SAMPLES 





Mass (g) Freezing 
Time Delay 
(min) 
1 0.0205 16  
 
0.0354 41 
2 0.0158 28  
 
0.0301 108 
3 0.0254 20  
 
0.0613 64 
4 0.0256 14  
 
0.0363 52 
5 0.0294 14  
 
0.0757 39 
6 0.0197 17  
 
0.0256 50 
Mean ± SD 0.0227± 
0.0049 
18 ± 5  
 
0.0441 ± 0.0198 59 ± 25 
 
Freezing Time Delay includes the gross dissection time during which fascicles were 
separated from the whole nerve and the time required for fascicle segment implantation 








Figure 3. 1 Lesion-Freezing delay of the nerve samples collected during Stage I and 
Stage II .  
Freezing time delay was significantly longer (Paired two-tailed t-test: t(5)=4.863, p = 
0.0046) for post-lesion nerve samples (59 ± 25 min; Mean ± SD) compared to pre-lesion 










Figure 3. 2 Differentially expressed genes involved in regulating glial cell proliferation. 
Abundance of the transcripts levels of 8 genes annotated with the positive regulation of 
glial cell proliferation (GO:0060252). The two genes annotated (SOX10, PLAG1) with 
negative regulation of glial cell proliferation (GO:0060253) were downregulated transcript 
levels in stage II nerve tissue. Differential expression cutoff criteria were |log FC| >1, p < 












Figure 3. 3 Analysis of growth factors activity. 
Differentially and significantly expressed growth factors defined under Growth Factor 
Activity according to gene ontology (GO:0008083). Differential expression cutoff criteria 











Figure 3. 4 Analysis of the key genes involved in the axonal repair. 
 
Heat map obtained for the differentially-expressed genes that are annotated with the 
ontology terms: Regulation of Axons Regeneration (GO: 0045773) and Axons Extension 
(GO: 0050772). The transcript levels were obtained from the sural nerve tissue of 6 
participants during stage II surgery and compared to that of stage I. The expression of main 
positive regulators of Axonogenesis. such as PLXNC1 gene, was upregulated at two weeks 
after the initial nerve injury. Significant levels were determined at |Log FC| >1, p < 0.05 









Figure 3. 5 Analysis of neural synaptic plasticity two weeks after sural nerve injury.  
There was a significant abundance of the transcript levels of the genes (SHANK3 and KIT) 
that are positive modulators of the long-term neural synaptic plasticity in nerve tissue 




















Figure 3. 7 Comparison of the transcripts’ levels of differentially-expressed PD-related 
genes. 
Heat maps obtained from RNA-Seq data of stage II sural nerve tissue and compared to that 
of stage I. The abscissa indicates the participants and ordinate indicates A) PD mendelian 
genes and B) PD-Risk loci that were significantly and differentially expressed with 





















Figure 3. 8 Identification of transcriptional regulators of PD-related genes. 
The expression pattern of the differentially-expressed transcription factors (TFs) during 
stage II was compared to that of PD-related genes. The Correlation matrix was mapped in 
JMP Pro14 with |Pearson’s correlation| ≥ 0.8 and p-value < 0.05. Seven potential repressors 
were significantly upregulated in coordination with the subsequent downregulation of 5 PD-
related genes, while 13 TFs were significantly downregulated in a strong correlation with 










CHAPTER FOUR: THE NEURO-AVATAR PROJECT 
 
Abstract  
The implantation of peripheral nerve tissue and cells provides anatomical and 
functional restoration in a variety of CNS injury models. To date, the reported results of 
implanting peripheral nerve cells within the brain environment have been limited to the 
usage of rodent peripheral nerve tissue. Transplanting human peripheral nerve fascicles in 
the dorsal striatum of rodents have never been examined experimentally. Herein, we describe 
the survival, biodistribution, and host responses to human peripheral nerve tissue implants, 
harvested from human donors according to the protocol developed for the Phase I DBS-Plus 
clinical trial. Repair human Schwann cells (huSCs) persisted within the injured rat dorsal 
striatum through 6 months after implantation and displayed restricted biodistribution within 
the implantation site. Besides, histological comparison between injury-naive and 
conditioned implants (14 days after injury) was also reported. Further, studying the bio-
response of the brain tissue, using proton magnetic resonance spectroscopy, displayed signs 
of a positive influence of the PN implants on the integrity of the central neurons. 
Introduction 
Cell therapeutics have been one of the frontline approaches that aimed at promoting 





diversity of cell types, including transplantation of SCs, in the form of a peripheral nerve 
(PN) implant or as an injected-purified cell suspension, has been examined as a therapeutic 
strategy in various CNS injury animal models over the last three decades (Wiliams & Bunge, 
2012). This experimental approach was recently implemented clinically in Poland, where 
human SCs transplanted as PN implants showed indications for safety and efficacy in 
subjects with spinal cord injury (Tabakow et al., 2014).  
Our transcriptomic results reported in Chapter 3 add to our understanding of the 
repair potential adopted by the human PN two weeks after an injury. Yet, we still needed to 
assess the neurobiology of the conditioned PN implants following implantation in the 
midbrain. To our knowledge, all preclinical data supporting the safe and effective use of SCs 
upon transplantation, in the form of PN implants, into the CNS were almost exclusively 
employed in rodent‐derived cells (Bastidas et al., 2017). To date, no research study has 
examined the effects of human SCs when transplanted into the brain. Thus, to better learn 
about the survivability, distribution, and interaction of human SCs, when transplanted in the 
form of PN implants, we designed the Neuro-Avatar project. This xenotransplantation 
project aimed to examine cellular function and host response to human SCs when 
transplanted into the dorsal striatum of the athymic nude rat. Athymic nude rats are an 
immunodeficient strain of Sprague-Dawley rats with a reduced immune rejection of foreign 
tissue (Hanes, 2006). To better characterize the transplantation paradigm used in DBS Plus 
clinical trial, we utilized human PN fascicles harvested during Stage I and Stage II surgeries 
and implanted them in the brain of athymic nude rats. First, we studied the bioavailability 





assessed the host bio-response to the xenograft using the modern applications of in vivo 1H 
Magnetic resonance spectroscopy (MRS) (Ligneul et al., 2019). 
Experimental Design and Procedures 
Four human participants undergoing the DBS Plus trial have donated sural nerve 
fascicles. Grafts from the donated nerve fascicles were implanted in a total of 16 animals: 8 
brains were collected at two weeks post-surgery and 8 were collected six months post-
surgery. Within each group of 8 animals, 4 were implanted with human nerve tissue from 
Stage I surgery (injury-naive tissue), and 4 received nerve tissue from Stage II surgeries (in 
vivo- conditioned tissue).  
Harvesting of Human Peripheral Nerve Implants 
Experimental procedures, including handling and transplantation of human 
peripheral tissue, were approved by the IRB (B18-3211-M) of the University of Kentucky. 
Human peripheral nerve fascicles were obtained from 4 human subjects (aged 45-70 years) 
who are undergoing DBS-Plus surgery for Parkinson’s disease. The sural nerves were 
dissected, and the nerve fascicles were collected from stage I and stage II. The nerve fascicles 
were collected in sterile conditions, placed on ice, and transported from the operating room 
to the laboratory for grafting. Up to 9 nerve fascicles were harvested from 1 cm section of 






All animal procedures were approved by IACUC of the University of Kentucky and 
performed per NIH guide for the care and use of Laboratory animals. 23 adults male athymic 
nude male rats (Hsd:RH-Foxn1rnu) were obtained from Charles River Laboratories, 
Chicago, IL.  On average, the animals weighed 225g  ± 20, were at eight weeks of age, and 
were housed in micro-isolated cages and kept in a room designated for immunodeficient 
rodents with a 12-hr light/dark cycle. Autoclaved food and water were available ad libitum. 
Cages and bedding were changed every three days. Clinical observations, as well as health 
and mortality records, were noted. 
Animal Surgery 
The surgical field was prepared by laying out a sterile surgical drape over a preheated 
surgical warming pad set to 38-40 °C. The sterile, empty surgical cannula was mounted to 
the arm of the stereotactic frame. This cannula was a 20 gauge needle with the tip blunted 
and smoothed with a Dremel tool and an inner stylet of 0.1 mm diameter. Anesthesia was 
induced using 5% isoflurane with supplemental oxygen in an anesthesia induction box. After 
anesthesia induction, animals were secured to the stereotactic frame using a tooth bar and 
anesthesia nose cone with 2.5% isoflurane with supplemental oxygen. Ear bars (45° Non-
Rupture tip) were placed securely in both auditory canals and adjusted until the animal was 
symmetrically secured to the stereotactic frame. Animals were kept on surgical warming 
pads during and after surgery. The dorsal surface of the animal’s skull was shaved using an 





soaked in betadine solution followed by a wipe-down with two alcohol pads. After 
anesthesia induction, the animal was treated with the following: Rimadyl (10 mg/kg, SQ), 
Buprenorphine SR (1 mg/kg SQ), and Baytril (5 mg/kg IM). After making the skin incision, 
Bregma was located on the skull surface and a burr hole was made over the right stratum (1 
AP, -2.5 LM) and the dura carefully broken.  The cannula containing the PN implants, was 
lowered slowly at a rate of ~1 mm/minute. Once the target was reached (-4.5 DV), a 1 mm3 
of human PN implant was implanted in the right striatum. The cannula was removed slowly 
and the burr hole was sealed using bone wax. The surgical incision was stapled. The animals 
were transferred for recovery on a surgical warming mat. 
Histological Processing 
At the endpoints (2 weeks and six months post-transplantation), animals were deeply 
anesthetized using a single dose of pentobarbital (100 mg/kg IP) and 
then transcardially perfused with at least 250 mL of normal cold saline followed by 180 mL 
of 4% Paraformaldehyde (PFA). The brain was extracted and postfixed with 4% PFA for at 
least 24 hours. Following post-fixation, the implantation site was identified and cut into a 1 
cm section in brain mold and cryoprotected in 30% sucrose for three days. Cryopreserved 
brains were cut coronally into 40 µm thick sections and stored in 30% sucrose solution with 






To identify the transplanted human peripheral nerve cells and examine their 
interaction with the host CNS, immunostaining with antibodies against Human Nuclear 
Antigen (HNA) was employed. Tissue series from the transplanted brain sections were 
subjected to anti-HNA antibody together with DAPI (4′,6-diamidino-2-phenylindole). The 
primary antibody used was Mouse Anti-human HNA (1:500; Catalog#: ab191181, Abcam, 
Cambridge, MA). The fluorescent secondary antibody was Alexa conjugated goat Anti-
mouse IgG (1:500; Catalog#: ab150113, Abcam, Cambridge, MA). To ensure the specificity 
of observed immunostaining, both positive and negative controls were included during 
staining. Negative controls consisted of the incubation of the primary or secondary 
antibodies alone, in addition to a non-grafted and intact rodent brain collected after 6 months 
of the experiment. Positive Controls consisted of incubation of sections of human sural nerve 
collected during both stage I and stage II surgeries. The brain sections were transferred from 
their wells and washed once with PBS. The tissue was permeabilized using 0.2% Triton X-
100 for 5 minutes and then washed with PBS once. The slides were blocked with 5% goat 
serum, 1%Triton X-100 for 1 hour. Afterward the slides were incubated with the primary 
antibody in PBS, 0.1% goat serum overnight at 4’C. The next day, the slides were washed 
with PBS, 3x5 minutes, and incubated with fluorescence-conjugated secondary antibody in 
PBS, 0.1% normal serum for 1-2 hours at RT in the dark. Finally, the slides were rinsed in 





Magnetic Resonance Spectroscopy  
Magnetic Resonance Spectroscopy is possible on any nucleus producing a magnetic 
moment. The metabolically active proton nuclei (1H) is the most sensitive for NMR, and it 
allows us to detect a large number of important amino acids and metabolic pathways’ end 
products like N-acetyl aspartate (NAA) and Creatine (Cr) /phosphocreatine. In healthy brain 
tissue, the most prevalent resonance originates from the methyl group of NAA at 2.02 
ppm (Moffett et al., 2007). The chemical shifts are referenced in regard to that of 3-
(trimethylsilyl)1-propanesulfonic acid at 0.00 ppm. NAA is exclusively localized in the 
central as well as the peripheral nervous systems. NAA has been used as a marker for viable 
neurons as it is only found in neurons, and its concentration decreases in the 
neurodegenerative diseases which affect the CNS (Schuff et al., 2006). The NAA 
concentration is not uniform and varying between gray matter (8-11 mM) and white matter 
(6-9 mM) (Moffett et al., 2013). The methyl and methylene protons of creatine and 
phosphocreatine resonate at 3.03 ppm and 3.93 ppm. Since the sum of both forms, total 
creatine (tCr), is constant in adulthood, the later can be used as a suitable in 
vivo concentration reference. Glutamate and Glutamine peaks were determined at 2.1-2.5 
ppm and 3.7 ppm, respectively. Brain morphology and metabolism were assessed using 
T2WI magnetic resonance and imaging MRI and MRS (7-tesla Horizontal 
bore magnet; Bruker/Siemens scanner) at three months post-grafting in Neuro-Avatar 
animals. Two animals were used for MRS studies at three months post-grafting. The first 
one was a neuro-avatar athymic rat that has received a stage II human nerve tissue implanted 
into the right dorsal striatum. The second animal was a sham animal where a cannula with 





isoflurane. The heads of the rats were fixed in a body retainer, the respiratory rate 
was monitored, and the body temperature was maintained at 37 oC with a body heating 
pad. Spectra were acquired at TR/TE/NS = 2500/3/200 for ipsilateral as well as the 
contralateral striatum with the voxel (volume = 3×2×3 mm3) placed just next to the 
implantation trajectory. Ipsilateral metabolic concentrations were normalized to that of the 
contralateral (intact) hemisphere before comparing the two treatment groups.  
Results 
Accuracy and Precision of Stereotactic Surgical Implantation Procedure 
Gross histology of 5 transplanted brains showed that some of the transplantation 
trajectories did not reach the deep targets in the dorsal striatum. Some of the trajectories 
were deflected when passing through the corpus callosum. This could partially be caused by 
the tract made by the blunted cannula in the brain tissue leading to lateral deviation of the 
trajectory in fibers-dense brain areas like in corpus callosum. However, the grafted brains 
with deviated trajectories were not excluded from the final analysis since the main objective 
of the experiment was to assess the viability of the human nerve cells post-implantation in 
the central nervous system environment. 
Long-Term Survival Of Human Sural Nerve Implant After Implantation 
Human Schwann cell transplantation, in the form of PN implants, in the brain of 





4.1). At two weeks post-implantation, animal brains implanted with pre-degenerated PN 
implants (Stage II) contained a higher count of +HNA cells than the animals implanted with 
PN tissue that were harvested from stage I (figure. 4.2). Second, transplanted +HNA human 
cells derived from stage I PN tissue significantly are significantly reduced 6 months after 
transplantation. However, the viability of human cells was significantly higher in animals 
receiving implants from stage II rather than from Stage I samples (figure 4.3). In addition to 
that, the cystic cavity and the surrounding edema were smaller at 6 months post-implantation 
from stage II implants. 
Brain Reaction To Human PN Implants 
Brain morphology and metabolism were assessed using an in vivo proton magnetic 
resonance spectroscopy (MRS). Proton spectra (Figure 4.4) were acquired in a cubic 
volume of 18 mm3 in the right striatum of sham and avatar groups, and the concentration 
ratios of N-acetylaspartate/choline (NAA/Cr) and other metabolites (Myo-inositol (Ins), 
Taurine (Tau)) were determined after identifying their respective peaks on the spectra 
(Figure 4.5). One animal was randomly chosen from each group to undergo the MRS study 
at three months of the surgery. Brain T2WI showed a similar insertion trajectory with mild 
hyperintensity at the implantation socket of the avatar brain. The N-acetylaspartate/choline 
(NAA/Cr) ratio, a neuronal marker, measured by MRS inside the striatum of the avatar brain 
showed a mild increase around the implant tip. The astrogliosis marker, Ins, was slightly 
increased in comparison to the sham animal. Tau, a marker of inhibitory neurons, was 







In response to peripheral nerve injury, Schwann cells transdifferentiate and gain new 
potential to proliferate, survive, and migrate in a hypoxic PNS environment (Chang et al., 
2011; Yao et al., 2016; Yu et al., 2012). Our goal is to identify the cellular viability and 
molecular changes after transplanting conditioned and pre-injured human peripheral nerve 
implant in the deep brain areas. To our knowledge, this is the first study that utilizes fresh 
and in vivo conditioned human peripheral nerve implants to the rat’s striatum. To avoid 
rejection of the nerve xenografts, this Neuro-Avatar project used athymic nude rats which 
are immunocompromised animals and have been successfully utilized in xenotransplantation 
research (Bastidas et al., 2017; Hanes, 2006). Human sural nerve tissue, donated by patients 
with PD participating in our DBS Plus clinical trial, were implanted in the dorsal striatum of 
the animals. We have shown that huSCs remained viable in the dorsal striatum up to six 
months post-transplantation (longest period examined). The implanted human derived cells 
demonstrated limited migration outside the grafting socket, a low proliferation rate, and no 
tumorgenicity features. When compared to Stage I implants, the Stage II implants displayed 
a higher cell count and viability in vivo. This is consistent with previous studies that indicated 
following a nerve injury, the distal stump undergoes Wallerian degeneration which 
optimizes cells’ long-term viability and endurance (Gordon, Wood, & Sulaiman, 2019; Yang 
et al., 2008). 
In this study, we report the implementation of T2WI MRI and proton MR 
spectroscopy to measure the biochemical response of the host striatum to conditioned-human 
(Stage II) PN implants. Brain MRS is a non-invasive method to analyze the concentration of 





allows us to acquire noninvasive metabolic data and help to monitor subtle changes in health 
and disease states in humans as well as in animal models (Bozza et al., 2010; Cho, Choi, 
Lee, & Kim, 2003; Manganas et al., 2007). In comparison to the sham group, we observed 
that the relative concentration of NAA was increased around the implant and at the borders 
of the substantia nigra. N-acetylaspartate has been used as an in vivo biochemical marker for 
neurons integrity and neurogenesis (Moffett & Namboodiri, 1995; Moffett, Ross, Arun, 
Madhavarao, & Namboodiri, 2007). The observed increase in NAA levels indicates 
enhancement of neuronal integrity that is consistent with the RNA-Seq analysis findings 
reported in Chapter Three, which demonstrated that pre-degenerated (Stage II) PN implants 
embrace a transcriptome profile that drives neurogenesis and axonal regeneration. We also 
observed a slight increase in Ins surrounding the implant, which is consistent with predicted 
gliosis (Haïk et al., 2008) produced by host astrocytes in response to the implantation 
procedure (Reier, 2012). However, this gliotic reaction was not noticeable on T2WI images, 
in contrary to other studies which reported significant CNS gliosis in response to fetal nigral 
grafts (Barker, Dunnett, Faissner, & Fawcett, 1996; Chi & Dahl, 1983; Lee et al., 2008). 
These results support incorporating MRS analysis in the DBS Plus clinical trial to improve 
our evaluation of brain response to PN implants in human subjects. 
Conclusion 
In conclusion, throughout this study, we investigated the viability and function of 
human Schwann cells following implantation of human nerve implants into the dorsal 
striatum. We have demonstrated that sural nerve implants collected from PD patients can 





nerve, induced during stage I of DBS surgery, incites the Wallerian degeneration 
processes in vivo; thus, prompting the proliferation of huSCs and enhancing their survival 
potential when collected at two weeks post-injury during the Stage II surgery of DBS 
procedure. We also demonstrated that nerve implants lead to striatal cell protection and 
central axons growth support. The histological and in vivo spectroscopy results do not 
display changes indicative of toxicity while showing signs of host striatal environment 
reacting positively to the nerve implants following implantation. Future studies employing 
transplantation of proregenerative nerve tissue in the transgenic animal model of PD will 







Figure 4. 1 Gross histology of Avatar brain. 
A) Nissl stained-coronal section of 40 μm thickness with human PN implant located in the 
right striatum (black arrow indicates the transplantation trajectory). B) MRI coronal section 












Figure 4. 2 Human PN derived cells remain viable in rat brain. 
The immunofluorescence staining results showed that the HNA labeled cells remain viable 









Figure 4. 3 Survivability of the implanted autologous PN-derived cells. 
Implanted PN cells survived for 6 months post-implantation in the rat brain. There is greater 
viability when the cells were transplanted from Stage II (in vivo pro-regenerative or 
conditioned tissue) in comparison to Stage I cells. At two weeks following implantation into 
the striatum, nerve implants collected from Stage II DBS Plus displayed a significantly 
higher count of HNA positive SCs, compared to nerve implants harvested from Stage I 
surgery. Stage I implanted cell count was significantly decreased six months post-
implantation. At six months, human SC viability was significantly higher in animals 
receiving implants from stage II compared to Stage I. Statistical significance indicated a 
*p<0.05 or **p<0.01. 
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Figure 4. 4 In vivo 1H MR spectroscopy analysis of brain metabolites.  
 
(A) Spectra obtained and brain MRI images of the sham and human PN transplanted groups, and the relative amounts of N-








Figure 4. 5 Concentration ratios of brain metabolites as identified by 1H MRS. 
The relative concentrations in the grafted striatum were compared to the intact contralateral 
side within each group (N=1). An increase of the neuronal marker (NAA) as well as a mild 
increase in the gliosis metabolite (Inositol) was observed surrounding the PN implant in 






CHAPTER FIVE: DBS PLUS CLINICAL TRIAL 
 
Introduction 
With no known cure, disease modifying therapies are one of the greatest unmet 
medical needs in the treatment of neurodegenerative diseases like Parkinson’s disease (PD) 
(Kalia, Kalia, & Lang, 2015). Prior cell therapies investigated for replacing degenerating 
dopaminergic cells in the substantia nigra pars compacta (SNc), including fetal nigral cells, 
autologous carotid body cells, and bone marrow-derived mesenchymal stem cells, have 
failed to alter the progression of the disease (Yasuhara, Kameda, Sasaki, Tajiri, & Date, 
2017). On the other hand, direct administration of non-neuronal cells that can deliver 
trophic factors has demonstrated therapeutic potential in protecting the sick neurons and 
possibly ameliorating the toxic environment in the brain (C. Chen et al., 2020). In 2013, 
our research group initiated a clinical trial to investigate the hypothesis of using 
reprogrammed Schwann cells (SCs), in a form of autologous peripheral nerve (PN) 
implants, to deliver crucial repair molecules to the degenerating dopaminergic neurons in 
PD patients undergoing DBS surgery (a procedure we have termed DBS Plus) (van Horne 
et al., 2017). This clinical study was the first to investigate the use of autologous PN tissue 
implants in conjunction with DBS, an FDA-approved adjunctive therapy to treat the 
symptoms of PD. The main goal of the initial pilot study was to determine the safety, 
feasibility, and tolerability of implanting PN implants at the time of DBS surgery. Eight 





demonstrated safety and feasibility of implanting sural nerve tissue containing autologous 
SCs into the SNc  from conditioned PN tissue. 
To further validate the safety and to explore the potential “open label” efficacy of 
this therapeutic approach, we have optimized the sample size in our ongoing studies 
(clinicaltrials.gov, registration no. NCT02369003). The study reported here includes 
participants with PD who elected to receive DBS plus pre-injured sural nerve tissue into 
the SNc with targeting of DBS leads to the internal segment of the Globus Pallidus (GPi). 
One benefit of this approach is that the location of the DBS leads is remote enough from 
the SNc tissue implants so that they can be readily visualized with MR imaging. We 
continue to investigate questions regarding dosing and optimization of bilateral placements 
of the PN tissue implants to help lay the foundation for a blinded Phase IIa trial to optimize 
the efficacy of the combined DBS and cell-based intervention. 
Patients Selection 
This clinical study is a part of an open-labeled Phase I clinical trial 
(clinicaltrials.gov, registration no. NCT02369003) conducted by the Brain Restoration 
Center at the University of Kentucky Medical Center. The study aims to investigate the 
safety, feasibility and motor outcome of the DBS Plus intervention in two groups of PD 
participants. Group A includes participants (N=18) who received  Five, 1 mm3 sections of 
pre-injured sural nerve tissue into the SNc. Group B participants (N=9) received a double 
dose (2 sets of Five, 1 mm3 segments of nerve fascicle) of the sural nerve tissue. Both 
groups of participants met the inclusion and exclusion criteria described in Chapter Two 





the control group, we collected UPDRS III OFF-medication scores of patients with PD 
(w/o any history of surgical intervention) from the PPMI Database (Parkinson’s 
Progression Markers Initiative). We collected UPDRS III data for 80 control subjects, 
matched by age (45-75 years) and disease severity (Baseline OFF UPDRS III 30, Hoehn 
& Yahr II-IV), for whom at least two years of follow-up was available. Since no OFF-
Stimulation scores were reported in the database for PD subjects who elected to receive 
DBS, such a group of subjects (+DBS, w/o implant) was not included in our comparison 
analyses. We compared UPDRS III total OFF Medication/ OFF Stimulation scores, 
parkinsonian motor subcomponents, change from baseline, striatal reserve measured by 
Levodopa Response (OFF-ON difference), and adverse events at the end of one and two 






The statistical analyses and data plotting were performed using GraphPad Prism 8. 
The quantitative data were plotted using mean  SEM. Analysis of the motor scores 
between the groups at different time points was done using a Two-way ANOVA followed 
by Tukey’s multiple comparison test. A comparison between the lateralized scores at the 
Two-year time point was made using Wilcoxon Signed-Rank test. A multiple comparison 
test was used to compare the motor subcomponents of the UPDRS III scale. A Spearman 
correlation was used to test the relationship between the Levodopa Response at baseline 







Patient Summary  
Twenty-seven participants (20 males and 7 females) met the criteria for 
participation in the study (Table 5.1). 18 participants of group A and 9 of group B were 
randomly assigned to receive unilateral implantation of single and double dose of PN 
implants respectively. The mean age (SD) of group A participants was 62.9 ± 8.1 years, 
and the mean disease duration was 9.3 ± 4.4 years. The mean age of group B participants 
was 61.88 ± 6.66 years, and the mean disease duration was 9.3 ± 4.18 years. The baseline 
UPDRS III OFF scores of group A participants ranged from 20 to 56, while those of group 
B participants ranged from 22 to 75. One participant of group A has failed to follow up 
while another participant has sadly passed away due to non-study related causes 20 months 
post-surgery. Hence, a total of 16 participants of group A have completed their follow ups. 
Only 8 participants of group B were able to complete their follow up assessments at the 
12-month time point. For monitoring safety and adverse event reporting, each participant 
was evaluated by a movement disorder specialist at the University of Kentucky Medical 
Center and was in close communication with our study team throughout the study. 
Safety of DBS Plus 
All adverse events were submitted to and reviewed by the Data and Safety Monitoring 
Board (DSMB) at the University of Kentucky. One adverse event, superficial cellulitis 





mild. The infection was treated with oral antibiotics. Most of the participants complained 
of ankle paresthesia and numbness, which was expected and consented as a result of 
sectioning the sural nerve. Three adverse events (urinary retention, headache, and dyspnea) 
were mild, related to the DBS surgery and the general anesthesia (but not to the 
implantation procedure), and resolved without further intervention. Three events, included 
falls, were considered to be mild, not serious, and not related to the implantation procedure 
as well. One event, hypomania, was mild, not serious, and was related to DBS stimulation 
and resolved promptly after changing the stimulation of the more proximal set of contacts 
of the stimulating electrodes. With regards to DBS surgery, there were no observed 
infections, hardware malfunctions, or skin erosions. Concerning feasibility, all participants 
underwent successful sural nerve resection and tissue implantation without complications 
or significant delay. 
MRI Imaging  
Post-op imaging was performed using a 1.5T MRI to verify targeting of the DBS electrodes 
and the tissue implant location. The MRI images were performed within 48 hours post-
surgery. There was no evidence of edema on the T2 weighted images (T2WI) and no 
enhancement on the T1WI contrast images. Post-op MRI images were fused to pre-op CT 
scan data and the implantation trajectories were mapped using Lead-DBS software (Hanes, 
2006) to verify the placement of the electrodes and the tissue implants in all participants 
(figure 5.1). There was no evidence of stroke, hemorrhage, or brain deviation resulting 






Analysis of the UPDRS III motor scores at a two-year follow up of participants 
who received DBS plus a single dose of PN implant (Group A) showed a remarkable motor 
improvement in comparison to the control PD group (Table 5.2). We observed a substantial 
improvement in motor score at the 6 month time point (UPDRS reduction of 7.82). This 
improvement in motor score persisted for 24 months post-surgery. This change from the 
baseline was significant (p<0.0001) when compared to Control PD subjects who continued 
to progress clinically and scored on average 6.53  10.6 more points (figure 5.2).  
Also, we report here UPDRS III scores of the participants who received DBS plus 
the double dose of tissue implants (Group B). Out of 9 participants from Group B who 
were consented and enrolled in the study, only one subject failed to follow up at a 12-month 
time point. This group of participants had on average an improvement in their motor scores 
by 8.25 points ± 11.46 one year after the surgery (Table 5.2). Although the motor outcome 
profile of Group A was similar to that of Group B, the latter group scored 1.62 points less 
at six months following the surgery (UPDRS OFF Change: -9.44 vs. -7.82 points) (Figure 
5.3).  
We further explored the UPDRS part III data by performing subgroup analysis of 
Group A participants to investigate potential differences among symptom subsets, 
including tremor, rigidity, bradykinesia, and axial symptoms (speech, facial expression, 
gait, posture, postural instability, and body bradykinesia), and between lateralized scores 
relative to implant placement (ipsilateral vs. contralateral). Analysis of the lateralization 
effect of the tissue implants showed a significant overall reduction in the UPDRS III motor 





5.4). Subgroup analysis of the parkinsonian motor signs demonstrated significant 
improvements in tremor and bradykinesia and minor improvements in rigidity and axial 
symptoms (Figure 5.5). 
Correlation between Levodopa response at baseline and motor outcome 
The Levodopa response was determined by the difference between the UPDRS III 
OFF and ON medications state. 16 subjects of group A, who completed their two-year 
follow-ups underwent the levodopa challenge test. Participants were assessed after 12–14 
h without anti-parkinsonian medication and then given their usual prescribed dose of 
levodopa/carbidopa tablets and they are re-scored 2 hours afterwards. In Figure 5.6, the 
analysis revealed that the motor performance postoperatively had a significant positive 
correlation with the levodopa response at baseline (r = 0.6794, p<0.0038). Participants with 
higher Levodopa response at the baseline tended to score less at two years after the surgery. 
We also intended to assess how each participant scored clinically relative to the thresholds 
for clinically important difference (CID). According to Shulman et al., (Shulman et al., 
2010) minimal, moderate, and large CIDs are 2.5, 5.2, and 10.8 points from baseline, 
respectively. In total, 12 out of 16 participants (75%) scored about the threshold for 
minimal CID. 
Discussion 
The results of this study support the concept of combining cellular therapy with 





biological therapy with the standard DBS surgery is anticipated to expand our 
understanding of the disease pathology and introduces a new era for disease-modifying 
treatments (Rowland et al., 2016). Research evaluating two main strategies for cell-
transplants in PD, using fetal nigral grafts or induced pluripotent stem cells, are ongoing in 
the TRANSEURO trial and GForce-PD initiative (Barker, 2019; Z. Chen, 2018). Their 
concept is based on replacing the degenerating dopaminergic neurons by implanted 
neurons, which might be able to synthesize dopamine in vivo. Nevertheless, these strategies 
have faced serious ethical and safety obstacles like the formation of teratomas, and 
treatment-induced dyskinesia (Christophersen et al., 2006; Knoepfler, 2009; Sonntag et al., 
2018) as well as some frustrating motor results (Graff-Radford et al., 2006). In comparison, 
the cell-based therapy used in our DBS Plus trial involves a neurorestorative approach to 
repair the nigrostriatal system. This research investigates the use of autologous peripheral 
Schwann cells as a source of regenerative growth factors to restore and protect the 
degenerating dopaminergic cells rather than replacing them. The main advantage of our 
approach is that the patients will be providing their autologous cells, which are harvested 
and implanted simultaneously with the standard DBS symptomatic treatment. 
This Phase I clinical trial was initially designed to test the safety and feasibility of 
implanting autologous peripheral nerve tissue into the substantia nigra in combination with 
DBS in patients with PD. Since the ethical requirement of beneficence renders the 
exclusion of the standard of care (DBS) unethical, we could not enroll in our clinical study, 
a control cohort of PD patients. Nonetheless, we compared the motor outcome of our study 





retrospective cohort included age and baseline-matched subjects with PD, who have 
received no surgical intervention, including DBS. 
The DBS procedure is approved for patients who have had PD for at least four years 
and whose symptoms are adequately responsive to medications. This surgical intervention 
alone has turned out to be a relatively safe surgical procedure to treat advanced PD 
symptoms. The adverse events of the combined therapy reported in this study were similar 
to the DBS surgery without transplantation (Bratsos, Karponis, & Saleh, 2019). Only one 
long-term adverse event, local cellulitis, was related to our implantation procedure and it 
resolved with oral antibiotics. Additionally, brain mapping and MRI imaging post-op 
showed accurate targeting of the tissue implants in the substantia nigra with no evidence 
of edema, hemorrhage, or signal abnormality along the graft trajectory. Additionally, we 
did not observe neither off nor on-therapy dyskinesias in our participants throughout the 
follow-up visits. Although these patients have received DBS, we argue that implant-
induced dyskinesia is not masked by the electrical stimulation since the DBS target (GPi) 
is distant (5 mm) from the implant location (SNc) and the patients are evaluated 12 hours 
off stimulation. 
In regards to the motor outcome, there was an overall decline in UPDRS III scores 
(-7.82, ± 9.1) during the first six months of the surgery in participants who received DBS 
plus the five pieces of sural nerve tissue. This reduction appears to be slightly greater (-
9.44, SD ± 9.3) in participants who received the double dose of tissue implants. Interestingly, 
it looks as though the improvement in UPDRS III scoring tends to be relatively stable for 





group who scored an increase of 6.53 points (SD ±10.6) at the two-year follow up similar 
to what was reported in another study (Vavougios et al., 2018). 
A comparison between ipsilateral versus contralateral UPDRS III motor scores 
showed improvements on both sides but a statistically significant difference in the scores 
contralateral to tissue implant location. The mild ipsilateral improvement, which has been 
reported by other surgical interventions for PD (Walker, Watts, Guthrie, Wang, & Guthrie, 
2009), might be due to regeneration of some non-decussating fibers connecting the 
midbrain and the striatum at the implanted side.  
In depth analysis of the UPDRS motor subcomponents showed that the most 
significant improvement was in the tremor and bradykinesia domains. We do not anticipate 
this improvement could be due to DBS therapy as DBS was turned off for 12 hours before 
motor testing. This should be sufficient time for most therapeutic effects of the DBS 
electrophysiological stimulation to dissipate (Temperli et al., 2003).  
To assess the importance of changes in UPDRS III scores clinically we evaluated 
our results relative to the CID thresholds as described by Shulman and his team (Shulman 
et al., 2010). Out of 16 participants who received bilateral DBS plus a single unilateral cell 
implant, 11 (69%) improved clinically above the minimal CID, three were stable, and 2 
participants scored higher (worse). 
Lastly, we analyzed the change in UPDRS III OFF score after two years in 
correlation with the absolute value of Levodopa response at baseline. The acute motor 
response to Levodopa following a minimum of 12 hours washout has been used as a guide 
in managing medical or surgical decisions in PD (Ganga et al., 2013). However, recent data 





increasing disease duration and progression (Pieterman, Adams, & Jog, 2018). In the group 
of participants who completed the two year follow up, there was a significant positive 
correlation between the amplitude of Levodopa Response at baseline and the reduction 
seen in the UPDRS III Off score. This analysis was consistent with the clinical 
improvement recognized in those subjects who scored beyond the threshold of the minimal 
clinically important difference. The results of this correlation may help us to better 
determine those participants who are expected to respond to this cellular therapy in future 
enrollments. 
One limitation of our study is the lack of a DBS only treatment group. It is difficult 
to recruit patients who receive the standard DBS surgery and to consent them for testing 
while being off stimulation and off medication for 12 hours. Another limitation is the lack 
of in vivo functional data to better assess the viability of the implanted SCs and their 
biological effects. The current FDA guidelines restrict any kind of in vitro manipulation or 
labeling of the cell implant tissues. However, an ongoing collection of post-op DaTscans 
should further help us evaluate the impact of the implants on regenerating the dopaminergic 
projections to the striatum.  
Conclusion 
In summary, this clinical study is exceptional because it provides prospective data 
on using cellular therapy in combination with DBS treatment in humans. Besides, this is 
the first study to investigate the influence of peripheral nerve cell implants in modifying 
the disease progression in PD.  The results support the clinical trial’s primary aim, which 





Throughout the analysis, we have demonstrated a favorable profile of extended safety and 
tolerability of the combined therapy. Our results have also shown the potential efficacy of 
the pre-conditioned implants in reducing the severity of the motor impairment in PD. 
There was a remarkable restoration of motor function, mainly on the side 
contralateral to the implant location, as assessed by the standard UPDRS scale part III. 
Most importantly, this restoration of function was not temporary, and it persisted up to two 
years post-intervention. Overall, the findings presented in this study worth further clinical 
investigation to better understand how PN cell implants were able to interact with the 







Table 5. 1 Demographic characteristics of the study subjects. 
 Age, Baseline scores, and duration of diagnosis are represented as Mean  SD. 
 





DBS Plus Double Dose 




Male 13 7 _ 
Female 5 2 _ 
Age (year) 62.9 ( 8.1) 61.9 ( 6.7) 59.4 ( 7.9) 
Baseline UPDRS III Off 38.4 ( 11.3) 42.8 ( 15.7) 34.4 ( 4.2) 
Duration of Diagnosis (year) 9.3 ( 4.4) 9.3 ( 4.11) > 5 years 
  
Table 5. 2 Change from the baseline of UPDRS III OFF scores  
Comparison of the change of UPDRS III OFF scores from the baseline of DBS plus a 
single dose of unilateral cell implants (group A) vs Control subjects with Parkinson’s 




Control PD DBS Plus 
(Group A) 
P-Value 
6 0.46 ( 6.7) -7.82 ( 9.1) 0.0129 
12 3.42 (10.4) -8.33 ( 9.3) <0.0001 
18 3.23 ( 9.6) -7.00 ( 9.1) 0.0013 







Figure 5. 1 3D Mapping of the implant location  
Coronal and anterior 3D view of the basal ganglia. The implantation trajectory and the final 
target of the tissue implants into the unilateral substantia nigra (in yellow) was mapped in 
Lead-DBS software. Globus Pallidus external segment (GPe), Globus Pallidus internal 









Figure 5. 2 Motor Outcome  
Motor evaluation of the study participants who received DBS Plus single dose of cell 
















































Figure 5. 3 Implant Dosage Motor Outcome 
Motor Evaluation of Study participants who received GPi DBS plus double dose cell 

































DBS Plus Single Unilateral Graft
Months





Figure 5. 4 Lateralization response to the cell implants. 
Analysis of the Change in UPDRS III Off scores in participants who received bilateral GPi 
DBS plus single cell implants showed a significant improvement on the side contralateral 











Figure 5. 5 Parkinsonian Subcomponents Analyses 
Analysis of the motor subcomponents of UPDRS III scale in 16 participants of group A at 
two-year follow up. The significant improvements in the OFF scores were in Tremor and 










Figure 5. 6 Correlation between Implant Response and Levodopa Response at baseline 
Correlation between the Levodopa Response at baseline and the Change in the motor scores 
at: A) 24 months of participants who received DBS and a single dose of nerve implants in 
the substantia nigra B) 12 months of participants who received DBS and a double dose of 
nerve implant. CID: Clinical Important Difference. Minimal (2.5 points), moderate (5.2 
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DISCUSSION AND FUTURE DIRECTIONS 
 
PN tissue as a source of cell-based therapy for neurodegenerative diseases has been 
investigated experimentally over the last four decades, and the past few years have shown 
renewed progress in its use in clinical trials. The research work demonstrated through this 
dissertation aimed to test how manipulating PN tissue can deliver vital therapeutic agents 
to CNS neurons to stop, slow, or reverse degenerative processes. Hence, PN tissue may 
have the ability to alter the progression of neurodegenerative diseases and contribute in the 
future to a true “disease-modifying therapy”. The peripheral nervous sytsem retains the 
ability to repair itself, unlike the CNS, and likely may guide us toward new therapies for 
neurodegenerative diseases and CNS trauma.  
Our extensive transcriptomic analysis described in Chapter Three provides robust 
scientific evidence of how a conditioning injury to the peripheral nerve drives the trans-
differentiation of Schwann cells into “repair cells”. The trans-differentiation process 
concurs with highly orchestrated changes in the levels of growth factors and repair 
signaling molecules. Some of those released growth factors, such as GDNF, have already 
shown efficacy in restoring and rescuing the structure and function of the dopaminergic 
neurons in preclinical studies. Overall, PN tissue appears to have the capacity to promote 
CNS plasticity and axon regeneration after an injury. We are aware that our transcriptional 
analysis needs to be replicated and validated by other genomic and proteomic studies. 
Nevertheless, we believe that our RNA-Seq analysis has helped to unmask key signaling 





capabilities of PN cells to minimize neuronal loss and induce axonal regeneration in 
neurodegenerative diseases like PD now becomes a central question.  
In Chapter Four, we detailed the establishment of the xenotransplantation animal 
model, the Neuro-Avatar project. This project aimed to help us evaluate the neurobiology 
of the sural nerve implants post-implantation in deep brain areas. We also reported the 
long-term viability of the conditioned sural nerve implants in comparison to injury-naïve 
PN implants. Survival and infiltration of the implanted human cells into the host brain were 
assessed by staining for human nuclear antigen. We also employed proton MRS technique 
to determine the brain reaction to the PN implant. Interestingly, we noticed an increase in 
the neuronal integrity marker (NAA) around the implant. The main advantage of the in 
vivo MRS study is that it can be safely translated to the DBS Plus clinical trial to evaluate 
better the local effects of the implant on the metabolism and regeneration of the 
surrounding midbrain neurons. 
While the clinical trials that have investigated implanting PN cells/tissue into the 
CNS are limited, those that have gone on to be published have demonstrated safety and 
feasibility outcomes with some suggestion of potential clinical improvement. In the last 
chapter of this dissertation, we tried to address the question of how the neurobiology of the 
conditioned sural nerve implant will correlate with clinical outcomes. Up to two years post-
implantation, the overall safety profile of combining DBS and autologous sural nerve 
implantation into the substantia nigra is similar to that of the DBS surgery alone. None the 
less, the preliminary analysis of the clinical outcome demonstrated very promising 





undergoing effort to enroll and collect UPDRS III data of participants who received only 
the DBS procedure will help us better validate those preliminary clinical results.  
In summary, the research described in this dissertation attempts to connect the dots 
between basic science and clinical trials in the neurodegenerative fields. The findings of 
these studies will significantly contribute to future translational studies in the areas of PNS 
injury and CNS diseases. We believe that the cell-based therapies using transplantation of 
autologous PN cells could become helpful in patients in the earlier stages of 
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